| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Submission example | BLA | — | Subscribe to access the data. | Biologics | Immunology | ||
BLA Submission example | BLA | — | Subscribe to access the data. | Biologics | Immunology | ||
BLA Submission example | BLA | — | Subscribe to access the data. | Biologics | Immunology |
Recent Updates
Recently added Catalysts
DBV Technologies S.A.$16.49
+0.41 (+2.55%)
C 51Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.09 B
EPS
-4.51
P/E Ratio
-
Value Trade
2.86 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
900.00 K
R&D Expenses
33.40 M
Operating CF
-49.10 M
Total Assets
266.40 M
Total Liabilities
58.40 M
Equity
207.90 M
D/E Ratio
12,345
-7.95 %
Week
-8.46 %
1 Month
-14.2 %
3 Month
32.03 %
6 Month
-69.5 %
5 Year
-92.16 %
All Time
Cash Data
Cash Position
229.20 M
Monthly Burn
16.37 M
Runway
11.9 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
151.10 K
52 Week Range
7.53 - 26.19
% held by Insiders
17.62 %
% held by Institutions
33.63 %
Enterprise Value
879.67 M
Total Shares
59.19 M
Short %
2.92 %
Float Shares
48.10 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for DBV Technologies S.A.
810Total events
9Upcoming
152Tier-1 (high impact)
2013 – 2027Coverage
Upcoming catalysts 9
Q2 2027
T2Runway Guidance Update
Cash and cash equivalents sufficient to fund operations into Q2 2027
2026-H2
T1BLA Submission
Planned BLA submission for VIASKIN Peanut Patch in toddlers aged 1-3 years in second half of 2026
TBD
T1Full Results
Full VITESSE results to be presented at future medical congresses and submitted for publication
TBD
T1Full Results
Full VITESSE results to be presented at future medical congresses and submitted for publication
TBD
T2Trial Initiation
Planned Phase 2 study of VIASKIN Peanut patch in peanut-allergic infants 6-12 months
TBD
T1Primary Endpoint Met
VITESSE Phase 3 study hitting primary endpoint triggers warrant acceleration
Event history 801
Q3 2026
◆BLA SubmissionRegulatory Filing
BLA submission anticipated in Q3 2026
peanut allergy in children aged 4 through 7 yearssource ↗
Q3 2026
◆BLA SubmissionRegulatory Filing
BLA submission anticipated in Q3 2026
peanut allergy in children aged 4 through 7 yearssource ↗
Q3 2026
Q3 2026
◆NDA SubmissionRegulatory Filing
BLA submission for Viaskin peanut patch in 1-3-year-olds
peanut allergy in 1-3-year-oldssource ↗
Jun 29, 2026
▲FDA Feedback ReceivedFDA Meeting
FDA provided actionable input on CMC and biostatistical elements; no additional data requested
peanut allergy in children aged 4 through 7 yearssource ↗
Jun 29, 2026
▲FDA Feedback ReceivedFDA Meeting
FDA provided actionable input on CMC and biostatistical elements; no additional data requested
peanut allergy in children aged 4 through 7 yearssource ↗
Jun 14, 2026
◆Oral PresentationPresentation
Presentation of THRIVE study design at EAACI 2026
peanut allergysource ↗
Jun 12, 2026
◆Oral PresentationPresentation
Presentation of VITESSE subgroup analysis at EAACI 2026
peanut allergysource ↗
Jun 9, 2026
◆Oral PresentationPresentation
Fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
Drug Pipeline Intelligence
C51
Pipeline Score $753M
Pipeline ValueFair Value
Valuation Signal8
Drugs Scored2.3x
rNPV / MCap Top 77%
Micro Cap (rank 211 of 911)
Percentile RankDBV Technologies S.A. carries a moderate pipeline score (51/100), with $2.5B risk-adjusted pipeline value, led by DBV712 in Allergy (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DBV712 Small molecule | Allergy, Peanut | Phase 3 | NCT05741476 | 50% | $1.5B | ACTIVE NOT_RECRUITING | 600 | AVERAGE | B (70) | Oct 1, 2029 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VIASKIN Peanut Patch Accelerated | peanut allergy | Phase 3 | 2026-06-08 | asthma: viaskin patch 48.3%, placebo 19.6%, risk difference 28.8, confidence interval 15.79, 41.76; food allergies: viaskin patch 46.8%, placebo 13.6%, risk difference 33.2, confidence interval 23.50, 42.83; atopic dermatitis: viaskin patch 47.2%, placebo 13.2%, risk difference 34.0, confidence interval 25.09, 42.94 Read More | DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 Read More | |
VIASKIN Peanut Patch Accelerated | peanut allergy | Phase 3 | 2026-06-08 | asthma: viaskin patch 48.3%, placebo 19.6%, risk difference 28.8, confidence interval 15.79, 41.76; food allergies: viaskin patch 46.8%, placebo 13.6%, risk difference 33.2, confidence interval 23.50, 42.83; atopic dermatitis: viaskin patch 47.2%, placebo 13.2%, risk difference 34.0, confidence interval 25.09, 42.94 Read More | DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 Read More | |
VIASKIN Peanut Patch Accelerated | peanut allergy | Phase 3 | 2026-06-08 | asthma: viaskin patch 48.3%, placebo 19.6%, risk difference 28.8, confidence interval 15.79, 41.76; food allergies: viaskin patch 46.8%, placebo 13.6%, risk difference 33.2, confidence interval 23.50, 42.83; atopic dermatitis: viaskin patch 47.2%, placebo 13.2%, risk difference 34.0, confidence interval 25.09, 42.94 Read More | DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DBVT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DBVT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DBVT▲ +11.1%on this news
Bilan semestriel du Contrat de Liquidité de DBV Technologies avec ODDO BHF
DBV Technologies has released its semi-annual report on its liquidity contract with ODDO BHF. The report highlights an increase in liquidity holdings, with 146,321 shares and €396,088.22 as of June 30, 2026. The company executed 1,989 buy transactions and 2,012 sell transactions during the first half of 2026, indicating active trading.
Read more →DBVT▲ +11.1%on this news
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies released its Half-Year Report on the liquidity contract with ODDO BHF, showing a significant increase in shares held in the liquidity account. As of June 30, 2026, the account held 146,321 shares and €396,088.22. The report details trading activities, including 1,989 buy and 2,012 sales transactions, indicating active market participation.
Read more →DBVTDBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
DBV Technologies has provided an update on its Biologics License Application (BLA) for the VIASKIN® Peanut Patch aimed at children aged 4 to 7. The company is working closely with the FDA to ensure a comprehensive review process and expects to submit the BLA in the third quarter of 2026. The FDA has not requested additional data, indicating a positive collaboration.
Read more →DBVTDBV Technologies intégrera l’Indice Euronext Tech Leaders
DBV Technologies has announced its integration into the Euronext Tech Leaders index, effective June 22, 2026. This index aims to showcase high-growth European tech companies to institutional investors. DBV's CEO expressed pride in this recognition, attributing it to their scientific approach and advancements in developing the VIASKIN® Peanut patch for treating peanut allergies.
Read more →DBVTDBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
DBV Technologies has been included in the Euronext Tech Leaders index, effective June 22, 2026. This recognition underscores the company's growth and innovation in the biopharmaceutical sector, particularly in developing treatments for food allergies. CEO Daniel Tassé expressed optimism about the increased awareness and opportunities this inclusion brings for the company and its mission.
Read more →DBVTDBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies has announced a revision in its participation at the Goldman Sachs 47th Annual Global Healthcare Conference, where management will engage in 1-on-1 investor meetings. However, CEO Daniel Tassé will not attend the fireside chat due to travel disruptions. The company continues to focus on developing treatments for food allergies using its proprietary VIASKIN® patch technology.
Read more →DBVTDBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
DBV Technologies announced positive results from its Phase 3 VITESSE study of the VIASKIN Peanut Patch, demonstrating significant efficacy in children with peanut allergies and comorbid atopic conditions. The company will also preview its THRIVE study, aimed at infants aged 6-12 months. Both studies will be presented at the EAACI Congress 2026 in Istanbul.
Read more →DBVT▼ -5.6%on this newsshared move
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, scheduled for June 9, 2026. CEO Daniel Tassé will engage in a fireside chat, highlighting the company's focus on developing treatments for food allergies using their proprietary VIASKIN® patch technology. The event will be accessible via a live webcast and archived replay.
Read more →DBVTDBV Technologies Announces the Results of its 2026 Combined General Meeting
DBV Technologies held its 2026 Combined General Meeting where shareholders approved all proposed resolutions. The meeting was chaired by Michel de Rosen, Chairman of the Board. DBV Technologies is advancing its proprietary VIASKIN patch technology aimed at treating food allergies through epicutaneous immunotherapy. The company is committed to improving care for individuals with food allergies.
Read more →DBVTDBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
DBV Technologies has announced the screening of the first participant in its THRIVE Phase 2 study, which evaluates the efficacy and safety of the VIASKIN® Peanut Patch for infants aged 6 to 12 months with peanut allergies. The study aims to assess the potential for ad lib consumption of dietary peanuts in this young population. This initiative is based on research suggesting that early interventions may positively influence allergy management and outcomes.
Read more →DBVTDBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
DBV Technologies announced that CEO Daniel Tassé will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The event will take place at Nasdaq in New York, and a live webcast will be available for those interested. DBV Technologies is dedicated to developing treatments for food allergies using its proprietary VIASKIN technology.
Read more →DBVTDBV Technologies Reports First Quarter 2026 Financial Results
DBV Technologies reported its first-quarter financial results for 2026, showing a cash position of $229 million, which is expected to fund operations into the second quarter of 2027. The company is focused on the Biologics License Application (BLA) submissions for its VIASKIN® Peanut Patch targeted at children ages 4 to 7. Despite a rising net loss of $47.6 million compared to the previous year, DBV is moving forward with its comprehensive development plan for addressing food allergies. Additionally, the upcoming THRIVE Phase 2 study will assess the effectiveness of the patch in infants aged 6 to 12 months.
Read more →DBVTCh tillon, France
DBV Technologies, a late-stage biopharmaceutical company, announced its financial results for the first quarter of 2026, revealing plans for upcoming Biologics License Applications (BLA) for its VIASKIN Peanut Patch aimed at treating peanut allergies in children. The company is also set to conduct a Phase 2 clinical trial focusing on infants aged 6 through 12 months. Despite a notable net loss of $47.6 million, it highlights a positive shift in net loss per share. DBV continues its transition towards commercial readiness while addressing food allergies with promising innovative therapies.
Read more →DBVTDBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4
DBV Technologies released its financial results for the year 2025, highlighting a rise in operating income while facing a substantial net loss. The company continues to advance its clinical development, particularly for the VIASKIN Peanut Patch aimed at peanut-allergic children. Despite the considerable increase in research and development expenses, management reports confidence in the company's financial position to sustain operations into 2027 due to recent funding activities. The anticipated regulatory submissions for product commercialization remain a focal point for the company moving forward.
Read more →DBVTDBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
DBV Technologies has announced the filing of its 2025 Annual Report on Form 10-K and its Universal Registration Document with relevant regulatory authorities. The filing includes crucial financial reports, governance details, and information regarding the company's share buy-back program. DBV Technologies continues to focus on developing treatments for food allergies using its innovative VIASKIN® patch technology. The company is currently involved in clinical trials for its food allergy programs, striving to improve care for individuals suffering from these conditions.
Read more →DBVTDBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
DBV Technologies announced its inclusion in the CAC Mid 60 and SBF 120 Indices as of March 23, 2026, following the annual review by Euronext Paris. This recognition reflects the company's progress in developing treatments for food allergies. CEO Daniel Tassé highlighted that this inclusion will enhance visibility within the investment community as the company prepares for commercialization. DBV Technologies focuses on leveraging its VIASKIN® technology to address food allergies, which affect millions globally.
Read more →DBVTDBV Technologies to Participate in Upcoming March Investor Conferences
DBV Technologies, a late-stage biopharmaceutical company, announced its participation in several investor conferences scheduled for March 2026. These include the Citizens Life Sciences Conference and the Leerink Partners Global Healthcare Conference. The company is focused on developing its VIASKIN patch technology for food allergies, benefiting from a growing market with high unmet needs. DBV's pipeline includes ongoing clinical trials targeting young children with peanut allergies.
Read more →DBVT▲ +10.8%on this newsshared move
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN Peanut Patch increased their eliciting dose at mon
DBV Technologies presented positive new data from their Phase 3 VITESSE study at the AAAAI 2026 Annual Meeting, highlighting the VIASKIN Peanut Patch's efficacy in treating peanut allergies in children. The study met its primary endpoint, showing that 46.6% of children receiving the patch achieved treatment responder criteria compared to only 14.8% in the placebo group. The additional findings indicate a consistent treatment effect across various patient profiles. DBV is planning to submit a Biologics License Application to the FDA in the first half of the year if approved.
Read more →DBVT▲ +10.8%on this newsshared move
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
DBV Technologies reported promising results from its Phase 3 VITESSE study of the VIASKIN Peanut Patch presented at the AAAAI 2026 Annual Meeting. The trial showed that 83% of children treated with the patch increased their allergic reaction threshold significantly compared to only 48% in the placebo group. The study confirmed the patch's efficacy across different patient subgroups, suggesting that it may help reduce the risk of allergic reactions. The company plans to submit a Biologics License Application (BLA) to the FDA in the first half of the year based on these results.
Read more →DBVT▲ +7.1%on this news
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
DBV Technologies has announced it will present additional data from the successful VITESSE Phase 3 study of the VIASKIN Peanut Patch at the AAAAI 2026 Annual Meeting. This presentation will focus on children aged 4-7 years and include discussions led by expert allergists about the future of epicutaneous immunotherapy in treating food allergies. Additionally, DBV will engage attendees at their exhibit booth to share insights on the EPIT approach. Despite the positive outlook, the company acknowledges the inherent risks associated with clinical trials and the regulatory approval process.
Read more →DBVTDBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
DBV Technologies announced that its CEO, Daniel Tassé, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit on February 12, 2026. This event highlights the company's focus on developing treatment options for food allergies using its proprietary VIASKIN® patch technology. DBV Technologies aims to provide non-invasive therapies for patients, especially children, suffering from food allergies. The event emphasizes the company's ongoing commitment to addressing unmet medical needs in immunological conditions.
Read more →DBVTDBV Technologies Announces 166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is sufficiently funded to support operations and
DBV Technologies announced the successful exercise of ABSA and BS Warrants, resulting in gross proceeds of $166.7 million. This funding is aimed at supporting operational activities and preparing for a potential launch of the VIASKIN Peanut patch for children aged 4 to 7 in the U.S. The financing was confirmed following positive results from the VITESSE trial. The company anticipates this funding will sustain operations for at least the next year, contingent on anticipated business activities.
Read more →DBVT▲ +10.5%on this news· ran to +23% by day 3shared move
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
DBV Technologies announced the successful exercise of warrants resulting in gross proceeds of €166.7 million. This funding will support operations and preparations for the potential launch of the VIASKIN® Peanut patch in children ages 4 to 7 years old in the U.S. The financing involved the issuance of new ordinary shares and warrants which are now fully exercised. The company anticipates that its current financial resources will sustain operations for at least the next year.
Read more →DBVTDBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years
DBV Technologies announced positive topline results from its Phase 3 VITESSE trial for the VIASKIN Peanut patch in children aged 4-7 with peanut allergies. The trial met its primary endpoint, showing that 46.6% of participants responded positively to the treatment compared to 14.8% in the placebo group. The safety profile of the patch was consistent with earlier studies, raising hopes for its potential approval. A Biologics License Application is planned for submission in the first half of 2026, capitalizing on the trial's findings.
Read more →DBVTDBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
DBV Technologies has completed the last patient visit in its Phase 3 VITESSE clinical trial for the VIASKIN Peanut patch, aimed at peanut allergic children aged 4-7 years. This double-blind, placebo-controlled study is the largest of its kind, involving 654 subjects across 86 sites. The company anticipates announcing topline results in the fourth quarter of this year.
Read more →DBVTDBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides
DBV Technologies has announced the completion of the last patient visit in the Phase 3 VITESSE clinical trial of the VIASKIN® Peanut patch for children aged 4 to 7 with peanut allergies. This marks a crucial step towards potentially providing a therapeutic option for these children. Preliminary results from the trial are expected to be shared in the fourth quarter of this year.
Read more →DBVTDBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation
DBV Technologies will participate in the 2nd Annual Guggenheim Healthcare Innovation Conference on November 11, 2025. Daniel Tassé, the General Director, will engage in a fireside chat during the event. A live webcast will be available, and an archived recording will be accessible for 90 days post-event.
Read more →DBVTDBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
DBV Technologies announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference, where CEO Daniel Tassé will engage in a fireside chat. The event is scheduled for November 11 in Boston. DBV is focused on developing innovative treatments for food allergies using its proprietary VIASKIN® patch technology, aiming to improve the lives of those affected.
Read more →DBVTDBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevronné du secteur, au poste de Directeur Commercial
DBV Technologies has appointed Kevin Trapp as Chief Commercial Officer, effective immediately. Trapp, who has over 30 years of experience in the biopharmaceutical industry, will oversee the global commercial strategy for the Viaskin® Peanut patch. The company is preparing to submit a Biologics License Application for peanut allergy treatment for children aged 4 to 7 in early 2026.
Read more →DBVTDBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
DBV Technologies has appointed Kevin Trapp as Chief Commercial Officer to lead its global commercial strategy for the Viaskin Peanut patch. This appointment comes as the company prepares for BLA submissions for children with peanut allergies in 2026. Trapp, who has over 30 years of experience, previously consulted for DBV and is expected to play a pivotal role in the commercialization efforts.
Read more →DBVT▼ -7.4%on this newsshared move
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
DBV Technologies has announced its participation in the ACAAI 2025 Annual Scientific Meeting from November 6 to 10 in Orlando, Florida. The company will host a Product Theater focused on early intervention in food allergy management, featuring discussions by leading allergists. The presentation will include details about a planned Phase 2 clinical study of the VIASKIN® Peanut patch aimed at peanut-allergic infants. Additionally, the company is expected to discuss compelling results from the EPOPEX study and its commitment to developing solutions for food allergies in young patients.
Read more →DBVT▼ -7.4%on this newsshared move
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Market: DBVT), (the "Company" or "DBV"), a clinical-stage biopharmaceutical
DBV Technologies has appointed Dr. Philina Lee as a new independent director on its Board of Directors, effective October 30, 2025. Dr. Lee replaces Daniel Soland and will also serve on the Compensation Committee. She brings significant experience in the biopharmaceutical sector, having previously held leadership roles and contributed to successful product launches. This appointment comes as DBV Technologies advances its ongoing clinical trials for its VIASKIN Peanut treatment for children with peanut allergies.
Read more →DBVTDBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
DBV Technologies has announced a sale of approximately $30 million in American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The company plans to issue 10,714,300 new ordinary shares, representing a dilution of roughly 5.96% for current shareholders. The successful capital raise is projected to extend DBV's cash runway until the end of Q4 2026, alleviating concerns about the company's financial stability. Results from ongoing clinical trials for treatment options in children are forthcoming, with regulatory submissions expected in the near future.
Read more →DBVTDBV Technologies Reports Third Quarter 2025 Financial Results DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026 DBV Technologies (Euronext: DB
DBV Technologies has released its financial results for the third quarter of 2025, showing a cash balance of $69.8 million, which provides a runway into the third quarter of 2026. Despite this cash increase, the company reported a net loss of $102.1 million for the nine months ending September 30, 2025, compared to a loss of $90.9 million in the same period the previous year. Due to ongoing losses and reliance on external financing, there are concerns about the company's ability to continue operations in the next year.
Read more →DBVTDBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Market: DBVT), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced th
DBV Technologies announced the immediate resignation of board member Daniel Soland, who expressed gratitude for his time on the board. DBV's management acknowledged his contributions since joining in 2015. The company will evaluate the timing and process for filling Soland's vacated position. Meanwhile, DBV Technologies is focused on its VIASKIN Peanut patch, which aims to provide treatment options for peanut allergies in children.
Read more →DBVTDBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
DBV Technologies has initiated an At-The-Market (ATM) program on Nasdaq that allows for the potential sale of up to $150 million of American Depositary Shares (ADS). The funds raised will primarily support the Biologics License Application (BLA) process for the VIASKIN Peanut patch, along with advancing development efforts for other product candidates. This program is a continuation of a similar financing strategy and is subject to certain regulatory limits in France.
Read more →DBVTDBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
DBV Technologies will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. CEO Daniel Tassé is set to engage in a fireside chat, which will be available via a live webcast and archived for later access. The company specializes in developing treatments for food allergies through its proprietary VIASKIN patch technology. This technology aims to modify immune responses to allergens, potentially transforming care for individuals with food allergies.
Read more →DBVTDBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT CUSIP: 23306J309), a clinical-stage biopharmaceutical company, tod
DBV Technologies reported financial results for the second quarter and half-year of 2025, revealing a net loss of $69.0 million compared to $60.5 million in the previous year. Operating expenses climbed to $69.9 million, largely attributed to new study launches. However, the company achieved a significant cash increase to $103.2 million due to recent financing efforts aimed at advancing its Viaskin Peanut program. Despite the positive cash position, concerns about long-term viability persist due to increasing losses and operating costs.
Read more →DBVTDBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
DBV Technologies has announced the filing of its 2025 Half-Year Report with the French market authority, Autorité des Marchés Financiers. This report, covering the period ended June 30, 2025, is accessible on the company's website and can be requested via mail or email. The company continues to focus on developing treatment options for food allergies, utilizing its proprietary VIASKIN patch technology, which aims to modify immune responses to allergens. DBV Technologies is committed to addressing significant unmet medical needs in this area.
Read more →DBVTDBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer
DBV Technologies has appointed James Briggs as the new Chief Human Resources Officer, succeeding Caroline Daniere. Briggs, a seasoned human capital executive, will lead crucial initiatives as the company transitions from a development-stage biotech to a potential commercial organization. His experience includes executive roles at MNG Health and Ciox Health, where he has successfully implemented talent strategies. The leadership change is seen as pivotal for DBV's operations and commercialization efforts, signaling a commitment to bringing innovative treatments for food allergies to market.
Read more →DBVTDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan
DBV Technologies has announced the screening of the first subject in its COMFORT Toddlers supplemental safety study, which focuses on peanut-allergic children aged 1 to 3 years. This Phase 3 study aims to gather crucial safety and efficacy data for the Viaskin Peanut patch, and will enroll approximately 480 subjects across multiple countries. The company anticipates that the data will support a Biologics License Application submission to the FDA in the second half of 2026, illustrating DBV's commitment to developing effective treatments for food allergies.
Read more →DBVT▲ +11.1%on this news
DBV Technologies to Participate in Upcoming EAACI Congress 2025
DBV Technologies announced its participation in the upcoming EAACI Congress 2025, scheduled for June 13-16 in Glasgow, UK. The company will present pivotal data regarding its VIASKIN® peanut patch and host a symposium focusing on recent research in food allergies. This event marks an opportunity for DBV to advance discussions on epicutaneous immunotherapy, particularly the relationship between allergists and patients. Despite some challenges in enrollment for the APTITUDE study, DBV remains committed to showcasing the potential of its therapeutic solutions for food allergies.
Read more →DBVTDBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
DBV Technologies held its 2025 Combined General Meeting, where shareholders approved all resolutions proposed by the company's Board of Directors. This outcome highlights strong support from shareholders as the company advances its strategic focus on food allergies and immunologic conditions. The company's proprietary Viaskin technology aims to provide innovative treatment options aimed at improving patient care in the food allergy space.
Read more →DBVTDBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
DBV Technologies has filed an addendum to its 2024 Universal Registration Document with the French market authority, providing updates to the Corporate Governance Report. This update highlights an exceptional compensation granted to the CEO, pending approval at the Annual Combined General Meeting scheduled for June 11, 2025. The addendum, along with the Universal Registration Document, can be accessed on the company's and regulatory authorities' websites.
Read more →DBVTDBV Technologies to Participate in the Citizens JMP Life Sciences Conference
DBV Technologies announced that its CEO, Daniel Tassé, will take part in a fireside chat at the Citizens JMP Life Sciences Conference on May 7, 2025. The event will provide a platform for discussing the company's ongoing work in developing treatments for food allergies. Attendees can access a live webcast and a replay of the discussion for 90 days post-event. DBV continues to prioritize advancements in immunotherapy with their proprietary VIASKIN patch technology.
Read more →DBVTDBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported fin
DBV Technologies has reported its financial results for the first quarter of 2025, showing a net loss of $27.1 million, slightly improved from the $27.3 million loss in the same quarter of 2024. The company's cash and cash equivalents have decreased significantly to $13.0 million from $32.5 million at the end of 2024, mainly due to clinical trial expenses. Despite this, DBV secured $125.5 million in financing to advance its Viaskin Peanut patch towards potential regulatory approval and market launch. The company continues to experience operational losses while preparing its first product for launch, if approved.
Read more →DBVTDBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
DBV Technologies has announced the filing of its 2024 Annual Report on Form 10-K and Universal Registration Document. The approved audited financial statements for the year ended December 31, 2024 revealed no changes from previously released unaudited statements. The report and related documents provide insight into the company’s ongoing efforts in developing treatment options for food allergies, particularly through its proprietary VIASKIN patch technology.
Read more →DBVT▲ +10%on this news· ran to +27% by day 3
DBV Technologies Announces Financing of up to $306.9 Million ( 284.5 Million) to Advance Viaskin Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved DBV secures $125.5 mi
DBV Technologies announced a financing of up to $306.9 million to advance its Viaskin Peanut patch, which targets pediatric peanut allergies. The funding will support the submission of a Biologics License Application (BLA) and a potential U.S. commercial launch, pending FDA approval. The financing was bolstered by positive developments from the VITESSE Phase 3 trial, which exceeded recruitment expectations. However, existing shareholders face possible significant dilution and the company's financial stability raises concerns regarding its operational sustainability.
Read more →DBVT▲ +58.6%on this news· ran to +97% by day 3shared move
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
DBV Technologies announced a financing deal of up to $306.9 million to support the development of its Viaskin Peanut Patch and prepare for a potential U.S. Biologics License Application (BLA) submission. This includes an upfront capital of $125.5 million and additional funds contingent upon warrant exercises. Although the financing is a significant positive step, it brings potential dilution risks to existing shareholders, alongside existing cash flow concerns that necessitated this funding. The company expects to have the necessary capital to maintain operations through mid-2026, aiming to launch the product if approved.
Read more →DBVT▼ -10.6%on this news· ran to -22% by day 3
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin Peanut Patch in 4 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H
DBV Technologies announced an agreement with the FDA to utilize safety exposure data from the VITESSE Phase 3 study for its Viaskin peanut patch in children aged 4 to 7. This agreement accelerates the anticipated timeline for a Biologics License Application submission to the first half of 2026, as the need for a supplemental safety study has been eliminated. The results of the Phase 3 study, which is the largest of its kind for peanut allergy in this age group, are expected to contribute significantly to the safety database at the time of submission. However, the company faces financial challenges, with dwindling cash reserves and operating losses affecting its future operations.
Read more →DBVTDBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
DBV Technologies is set to participate in the AAAAI/WAO Joint Congress from February 28 to March 3, 2025, in San Diego, CA. The company will present significant findings from its Phase 3 PEOPLE study, revealing promising long-term efficacy of the VIASKIN® peanut patch for treating peanut allergies in children. Notably, the percentage of treatment responders increased substantially over the study period, highlighting the treatment’s potential effectiveness. Additionally, DBV will host discussions and presentations on epicutaneous immunotherapy and its advantages during the congress.
Read more →DBVT▲ +10.4%on this news· ran to +43% by day 1
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN Peanut patch in toddlers 1 3 years th
DBV Technologies announced promising results from its EPITOPE Phase 3 Open-Label Extension Study, where the VIASKIN Peanut treatment showed continuous improvement in efficacy over three years. Notably, over two-thirds of subjects completed food challenges successfully, indicating significant treatment benefits. The data further supports the company's proposed labeling strategy for the FDA. With no new safety signals reported, DBV plans to advance its regulatory efforts, highlighting the potential of VIASKIN Peanut to change the landscape for peanut allergy treatments.
Read more →DBVTCh tillon, France, December 11 th , 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin Peanut Patch in Toddlers 1 3 Years-Old DBV and FDA aligned on key study design e
DBV Technologies has confirmed alignment with the U.S. FDA regarding an Accelerated Approval pathway for the Viaskin Peanut patch for toddlers aged 1 to 3 years. This agreement encompasses design elements for a required post-marketing confirmatory study, leveraging data from a Phase 3 study as an intermediate clinical endpoint. DBV is also advancing its plans to support distinct Biologic License Applications (BLAs) for different age groups. The FDA's ongoing collaboration indicates a promising regulatory environment for the patch's future commercialization.
Read more →DBVT▼ -6.1%on this news
DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatmen
DBV Technologies has announced its plan to change the ratio of its American Depositary Shares (ADSs) from one ADS to one ordinary share to one ADS to five ordinary shares. This change, expected to take effect on November 29, 2024, is aimed at complying with Nasdaq's minimum bid price requirements. Although this measure is anticipated to increase the ADS trading price proportionally, DBV acknowledges that there are no guarantees. The alteration will not affect the underlying ordinary shares and aims to enhance shareholder value while maintaining transparency about associated risks.
Read more →DBVTDBV Technologies Reports Third Quarter 2024 Financial Results
DBV Technologies reported its financial results for Q3 2024, revealing a cash balance of $46.4 million, down significantly from $141.4 million at the end of 2023. The company has been facing operating losses and cash flow challenges, leading to concerns about its ability to sustain operations beyond 2025. Despite these difficulties, DBV is continuing its clinical trials and seeks additional financing to support its research and development efforts.
Read more →DBVTDBV Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 3 years-old BLA submission under Accelerated Approv
DBV Technologies has announced positive regulatory updates for its Viaskin Peanut patch, aiming for an Accelerated Approval pathway for toddlers aged 1-3 in the U.S. and a similar indication in Europe. The FDA has confirmed that DBV meets critical criteria for accelerated approval and provided guidance on necessary safety studies. While the potential impact on peanut-allergic children and their families is optimistic, DBV faces financial challenges, with insufficient cash reserves to support operations over the next year. The company plans to address these challenges while advancing the patch towards regulatory submission.
Read more →DBVTDBV Technologies to Participate in Upcoming ACAAI 2024 Congress
DBV Technologies announced its participation in the ACAAI Annual Scientific Meeting happening from October 24 to 28, 2024, in Boston. During the event, the company will engage in discussions regarding optimal treatments for peanut allergies and sponsor the 33rd Annual FIT Bowl. The firm's participation comes following the completion of enrollment for its VITESSE study in children aged 4 to 7 years, as they continue to move forward with the regulatory process for their Viaskin® Peanut patch.
Read more →DBVT▼ -6%on this news
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin
DBV Technologies has successfully completed patient screening for its Phase 3 clinical trial, VITESSE, evaluating the Viaskin Peanut Patch in children with peanut allergies. This trial, which is the largest of its kind, involves over 600 subjects across multiple countries, including the U.S., Canada, Europe, and Australia. The company expects to advance towards a Biologic License Application submission based on the trial's outcomes. DBV's commitment to innovative approaches in treating food allergies highlights its mission to address significant unmet medical needs.
Read more →DBVT▼ -5.6%on this news
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
DBV Technologies has announced that its CEO, Daniel Tassé, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference scheduled for September 9, 2024. This event aims to showcase the company's innovative approaches to treating food allergies through its proprietary VIASKIN® patch technology. A live webcast will be available for interested parties, as well as a replay for 90 days post-event. The occasion underscores DBV's commitment to addressing significant unmet needs in immunologic conditions.
Read more →DBVTDBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
DBV Technologies provided updates on their Viaskin Peanut program and reported financial results for Q2 and the first half of 2024. Enrollment for the Phase 3 VITESSE study in children with peanut allergies is progressing well and is expected to conclude by the end of Q3 2024. Additionally, the company submitted a labeling proposal to the FDA to clarify treatment protocols for toddlers. While the company's cash position is currently extended into Q1 2025 due to cost-saving initiatives, concerns remain about financing capabilities in the future.
Read more →DBVTDBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
DBV Technologies filed its Half-Year Report for 2024 with the French market authority. The report is available for consultation and download from the company's website and the AMF, though currently only in French. DBV is dedicated to addressing food allergies through its proprietary Viaskin platform and is currently conducting trials for peanut allergies in young children. The company's commitment to transforming the care of food allergic individuals is emphasized in their ongoing research efforts.
Read more →DBVTDBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
DBV Technologies has announced that it will report its second-quarter financial results and provide a business update on July 30, 2024. The company will host a conference call and an audio webcast for interested participants. DBV is focused on developing treatment options for food allergies and other immunologic conditions through its proprietary Viaskin technology. The upcoming presentation aims to update stakeholders on the company's financial performance and progress in its clinical programs.
Read more →DBVTDBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
DBV Technologies has announced that its CEO, Daniel Tassé, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10th, 2024. This event will include one-on-one meetings with investors, allowing for direct engagement about the company's ongoing developments. DBV Technologies focuses on innovative treatments for food allergies using its proprietary Viaskin technology, indicating a commitment to addressing significant unmet medical needs in this field.
Read more →DBVTDBV Technologies Announces Plan to Implement ADS Ratio Change
DBV Technologies has announced an upcoming change in the ratio of its American Depositary Shares (ADS) to ordinary shares, aiming to regain compliance with Nasdaq's minimum bid price requirement. The new ratio will be implemented around June 7, 2024, effectively functioning as a one-for-two reverse ADS split. This adjustment is anticipated to have a positive impact on the ADS trading price, though the company cannot guarantee that the price will double post-change. The company continues to focus on developing treatments for food allergies using its Viaskin technology.
Read more →DBVTDBV Technologies to Participate in Upcoming EAACI 2024 Congress
DBV Technologies announced its participation in the upcoming EAACI 2024 Congress in Valencia, Spain, where key presentations will focus on data from their EPITOPE Phase 3 study related to peanut allergies in toddlers. The company aims to establish safety data for its epicutaneous immunotherapy product, Viaskin Peanut, particularly concerning accidental peanut consumption. Their involvement in the congress will include hosting a symposium and an exhibit, showcasing their ongoing research and commitment to addressing food allergies in children.
Read more →DBVTDBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatmen
DBV Technologies announced plans to change its American Depositary Shares (ADS) ratio from 1 ADS to 1/2 ordinary share to 1 ADS to 1 ordinary share, effective around June 3, 2024. This ADS Ratio Change resembles a one-for-two reverse split and aims to enable compliance with Nasdaq's minimum bid price requirement. While the company anticipates its ADS trading price to increase, it cannot guarantee that it will be twice the price prior to the change. The company's ongoing clinical trials seek to address significant unmet medical needs in food allergies.
Read more →DBVTDBV Technologies Announces Results of its 2024 Combined General Meeting
DBV Technologies conducted its 2024 Combined General Meeting, where shareholders approved all proposed resolutions from the Board of Directors. The company is committed to addressing food allergies through innovative therapies utilizing its Viaskin platform, which aims to re-educate the immune system. This meeting reflects strong support from shareholders, reinforcing DBV's strategic direction in the biopharmaceutical sector.
Read more →DBVT▼ -17.8%on this news
DBV Technologies to Participate in Upcoming Investor Conferences
DBV Technologies, a clinical-stage biopharmaceutical company focused on food allergies, announced that CEO Daniel Tassé will present at two upcoming investor conferences in May 2024. The presentations will occur at the Citizens JMP Life Sciences Conference on May 13 and the H.C. Wainwright BioConnect Conference on May 20. Live webcasts of each presentation will be available on the company's website, followed by a replay for 90 days. This engagement aims to enhance the company's visibility in the investment community.
Read more →DBVTDBV Technologies Reports First Quarter 2024 Financial Results and Business Update
DBV Technologies reported its first quarter 2024 financial results, indicating ongoing progress in its VITESSE study for the Viaskin Peanut patch, which is on track to complete enrollment by Q3 2024. The company appointed Robert Pietrusko as Chief Regulatory Officer, enhancing its regulatory expertise. However, DBV continues to face significant financial challenges, with a net loss of $27.3 million for the quarter and doubts regarding its ability to sustain operations without additional capital. Despite these challenges, the company maintains a cash balance of $101.5 million sufficient to fund activities through the end of 2024.
Read more →DBVTMontrouge, France
DBV Technologies reported its financial results for Q1 2024, highlighting progress in its Phase 3 VITESSE study for peanut allergies. The company surpassed the halfway point for patient recruitment and is gaining momentum with active enrollment in Europe and the UK. However, DBV faces a challenging financial outlook with a net loss of $27.3 million and concerns regarding its cash reserves, which may not support operations for the next year. The appointment of Robert Pietrusko as Chief Regulatory Officer bolsters the company's regulatory capabilities as it pursues further development of its Viaskin technology.
Read more →DBVTDBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical c
DBV Technologies has announced the filing of its 2023 Annual Report on Form 10-K with the SEC and its Universal Registration Document with the French market authority. These filings underscore the company's ongoing commitment to transparency and accountability in its operations. As a clinical-stage biopharmaceutical company, DBV is working on treatment options for food allergies, leveraging its Viaskin technology. The company is currently conducting clinical trials for its Viaskin Peanut product aimed at young children allergic to peanuts.
Read more →DBVTDBV Technologies Reports Full Year 2023 Financial Results and Business Update
DBV Technologies reported its financial results for the full year 2023, highlighting advancements in its Viaskin Peanut clinical development programs targeting peanut allergies in children. The company has strengthened its executive team in anticipation of submitting its Biologics License Applications. Despite a reported cash balance of $141 million, DBV faces ongoing financial challenges, including significant net losses and projections suggesting insufficient cash flow for continued operations. The company plans to seek additional capital to fund its research and development efforts in the coming year.
Read more →DBVTDBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
DBV Technologies has announced that it will host a conference call on March 7, 2024, to discuss its full year 2023 financial results and provide a business update. This event signifies the company's commitment to transparency and communication with stakeholders. DBV Technologies specializes in developing treatments for food allergies, utilizing its proprietary Viaskin technology. Interested parties can access the call via teleconference or through a live webcast on the company's website.
Read more →DBVT▼ -7.6%on this news
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
DBV Technologies announced its participation in the upcoming AAAAI 2024 Congress, scheduled for February 23-26 in Washington, D.C. At the congress, DBV will present two significant studies on the long-term safety of their Viaskin Peanut treatment, aimed at peanut-allergic children. The company is also sponsoring educational sessions and a Product Theater to discuss the clinical benefits of early intervention for peanut allergies. Exhibiting at the event will provide attendees with insights into ongoing clinical trials.
Read more →DBVT▼ -5.7%on this news
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
DBV Technologies announced positive two-year results from the EPOPEX trial of Viaskin Peanut in toddlers, showing marked improvements in treatment efficacy. By the end of 24 months, 81.3% of participants reached an eliciting dose of ≥1,000 mg, with no significant treatment-related adverse events reported. The ongoing study indicates a potential breakthrough in peanut allergy treatment for toddlers, suggesting both safety and effectiveness in real-world scenarios. These findings will be further presented at the American College of Allergy, Asthma, and Immunology annual meeting.
Read more →DBVTDBV Technologies to Present New Data at ACAAI 2023
DBV Technologies announced the presentation of new data regarding Viaskin Peanut at the upcoming ACAAI 2023 Annual Meeting in Anaheim, CA. The presentation will detail interim results from the Phase 3 open-label extension study of Viaskin Peanut in peanut-allergic toddlers. The company's Chief Medical Officer highlighted the importance of providing new treatment options for these patients, especially in the absence of FDA-approved alternatives. The meeting will also feature various discussions regarding allergy management and a booth for DBV Technologies.
Read more →DBVTDBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results DBV has received written feedback from the U.S. Food and Drug
DBV Technologies has received valuable feedback from the FDA regarding protocol design for its COMFORT safety studies, which aim to evaluate the efficacy of its food allergy treatment. The company plans to submit final protocols for these studies soon, aiming for enrollment to begin in Q1 2024. Despite this progress, DBV reported significant financial losses and a decrease in cash reserves compared to the previous year. The company's long-term prospects hinge on the successful alignment of its studies with regulatory expectations.
Read more →DBVTDBV Technologies to Report Third Quarter 2023 Financial Results and Business Update
DBV Technologies will hold a conference call on October 31, 2023, to discuss its third quarter financial results and provide a business update. The call will be accessible via teleconference and a live webcast will also be available. DBV Technologies is focusing on its Viaskin technology, which offers a novel method for immunotherapy via the skin. This indicates ongoing developments in their food allergy programs, including Viaskin Peanut.
Read more →DBVTDBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
DBV Technologies has appointed Virginie Boucinha as Chief Financial Officer, effective November 6, 2023. Boucinha has extensive experience in the pharmaceutical industry, having held senior positions at Pierre Fabre and Sanofi. This strategic move comes at a critical time for DBV, as it seeks to advance its regulatory and commercial efforts for Viaskin in the treatment of peanut allergies. She will replace the outgoing CFO, Sébastien Robitaille, in a planned transition period.
Read more →DBVT▲ +11.5%on this news
DBV Technologies to Participate in Upcoming Investor Conference
DBV Technologies announced its participation in the H.C. Wainwright Annual Global Investment Conference scheduled for September 11-13, 2023, in New York. CEO Daniel Tassé will take part in a fireside chat on September 12 and conduct one-on-one meetings with investors throughout the day. The event provides an opportunity for DBV to engage with investors and showcase its investigational immunotherapy platform, Viaskin. A live webcast will be available for those unable to attend in person, with a replay accessible on the company's website for 90 days post-event.
Read more →DBVT▼ -6.3%on this news
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results
DBV Technologies announced that it received feedback from the FDA regarding the design elements for its Viaskin Peanut safety studies, specifically for toddlers and children with peanut allergies. The two pivotal Phase 3 studies, named COMFORT Toddlers and COMFORT Children, will investigate safety over a 6-month period with a focus on adhesion and without requiring an oral food challenge for participation. Alongside this update, the company reported its financial results for Q2 and the first half of 2023, highlighting a cash balance of $174 million, although it noted increased operational cash usage and decreased financing activities compared to the prior year.
Read more →DBVTDBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update
DBV Technologies, a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast on July 31, 2023, to report its first half 2023 financial results and provide a corporate update. Participants will be able to access the event through specific teleconferencing numbers, with a live webcast available on the company’s investor relations website. DBV is focused on developing Viaskin, an investigational technology platform aimed at transforming treatment for food allergies.
Read more →DBVTDBV Technologies to Participate in Upcoming EAACI Congress 2023
DBV Technologies announced its participation in the EAACI Congress 2023, where it will present data related to peanut allergy treatment. Highlights include a focus on the unmet needs of toddlers suffering from peanut allergies and insights from the EPITOPE Phase 3 study on Viaskin Peanut. The company aims to engage with key opinion leaders and contribute to ongoing discussions in the allergy and immunology field. The symposium featured at the event will address the impact of peanut allergies on patients and families.
Read more →DBVT▲ +12.1%on this news
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin Peanut in Toddlers The New England Journal of Medicine (NEJM) published results that demonstrated ep
DBV Technologies announced the publication of their Phase 3 EPITOPE trial results in the New England Journal of Medicine, which evaluates the efficacy of Viaskin Peanut in toddlers with peanut allergies. The study revealed that Viaskin Peanut achieved statistically superior desensitization after one year of treatment compared to placebo. The results are positioned as a significant advancement for peanut allergy treatment in a demographic currently lacking FDA-approved options. The publication may assist in furthering the regulatory process following positive feedback from the FDA.
Read more →DBVTDBV Technologies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and cash equivalents of $192.3 million. DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical
DBV Technologies has released its financial results for the first quarter of 2023, indicating cash and cash equivalents of $192.3 million. Despite a solid cash position, the company has incurred a net loss of $20.5 million for the quarter, a decline from a $16.7 million loss in Q1 2022. Operating expenses also increased by 21% due to higher research and development costs, which raises concerns about financial sustainability moving forward. The company is focused on its investigational platform, Viaskin, which shows promise in the immunotherapy sector.
Read more →DBVTDBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
DBV Technologies announced a regulatory path for its Viaskin Peanut patch aimed at treating peanut allergies in toddlers aged 1 to 3 years after receiving feedback from the FDA. The FDA confirmed that the Phase 3 EPITOPE study met the success criteria for the primary endpoint and did not require an additional efficacy study. However, the agency mandated another safety study to bolster the existing data before proceeding with a Biologics License Application (BLA). DBV plans to submit a safety study protocol by the end of Q2 2023, while also managing a solid cash position of $192.3 million as of March 31, 2023.
Read more →DBVTDBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting
DBV Technologies, a clinical-stage biopharmaceutical company, announced the outcomes of its 2023 Ordinary and Extraordinary General Meeting held in Montrouge, France. Shareholders approved all resolutions proposed by the Board of Directors, reflecting their confidence in the company's leadership and direction. The approved resolutions are detailed on the company's website, emphasizing DBV's commitment to transparency and stakeholder engagement. Concurrently, the company continues to develop its Viaskin™ platform for immunotherapy, targeting food allergies.
Read more →DBVTDBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the Company s Phase 3 EPITOPE study met the pre-specified criteria for
DBV Technologies announced that the FDA granted written responses confirming the successful primary endpoint of its Phase 3 EPITOPE study for Viaskin Peanut, aimed at toddlers with peanut allergies. The FDA requires an additional safety study to augment existing data but will not mandate a new efficacy study. This response provides a clearer regulatory path towards a Biologics License Application (BLA) for the investigational patch in this age group. DBV plans to submit a proposed safety study protocol by the end of Q2 2023 while continuing work on other regulatory aspects.
Read more →DBVTDBV Technologies Update
DBV Technologies has updated investors regarding its financial standing, confirming that it does not hold any cash deposits or securities at Silicon Valley Bank. The company is actively developing Viaskin, a proprietary technology for delivering immunotherapy via the skin, particularly targeting food allergies. Notably, DBV is conducting ongoing clinical trials for Viaskin Peanut, seeking to provide effective solutions for peanut-allergic patients. The company emphasizes that projections regarding study milestones and outcomes are subject to various uncertainties and risks.
Read more →DBVTDBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 7 Years Old First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois in the VITESSE Clin
DBV Technologies has initiated the VITESSE Phase 3 clinical trial by screening its first patient, focusing on peanut-allergic children aged 4 to 7. The trial will evaluate the efficacy of the Viaskin Peanut patch, aiming to enroll 600 subjects across various countries. Clinical results are expected in 2025, which may support a future Biologics License Application. The trial represents a significant collaborative effort in addressing food allergies.
Read more →DBVT▼ -5.5%on this newsshared move
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
DBV Technologies reported its financial results for the full year 2022, revealing substantial growth in cash reserves, reaching $209.2 million. The company announced the completion of the EVOLVE study, which demonstrated positive user experience feedback regarding the modified Viaskin Peanut patch. However, the financial results also reflected a net loss of $96.3 million, indicating persistent challenges despite improvements in cash flow. The report aims to support upcoming applications for BLA based on ongoing clinical trials.
Read more →DBVT▼ -5.5%on this newsshared move
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
DBV Technologies has publicly filed its 2022 Annual Report on Form 10-K with the SEC and its 2022 Universal Registration Document with the AMF. These filings reflect the company's ongoing commitment to transparency. Additionally, both documents are readily accessible via the company's website, as well as the SEC and AMF websites. The company continues to focus on its Viaskin technology platform aimed at treating food allergies.
Read more →DBVTDBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
DBV Technologies announced it will report its full year 2022 financial results and host a business update on March 2, 2023. The conference call is scheduled for 5:00 p.m. ET and will include a webcast accessible on the company's website. DBV Technologies is focused on developing their Viaskin™ platform for food allergy treatments, underscoring their dedication to improving patient care.
Read more →DBVTDBV Technologies to Participate in Upcoming AAAAI 2023 Congress
DBV Technologies announced its participation in the AAAAI 2023 Congress set for February 24-27 in San Antonio, TX. The company will present two scientific posters showcasing efficacy and safety findings from the Phase 3 EPITOPE study on epicutaneous immunotherapy with Viaskin Peanut in pediatric patients. The presentations will highlight varying patient subgroups, including those with concomitant food allergies and atopic dermatitis. The event will also feature discussions from leading researchers on the role of skin immunology in food allergies, showcasing DBV's innovative approach in addressing peanut allergies in young children.
Read more →DBVT▲ +22%on this news· ran to +34% by day 3
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial DBV expects to initiate patient screening in Q1 2023 with the last patient screened by 1H 2024 and topline results anticipa
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration
Read more →DBVTDBV Technologies to Highlight New Clinical Data at ACAAI 2022
Montrouge, France, November 9, 2022 DBV Technologies to Highlight New Clinical Data at ACAAI 2022 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new clinical data on the use of
Read more →DBVTDBV Technologies Reports Third Quarter Financial Results and Business Update DBV closes Q3 with a cash balance of $213M DBV continues to practice budget discipline measures; cash used in operating activities decreased mo
DBV Technologies Reports Third Quarter Financial Results and Business Update DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2022. The quarterly
Read more →DBVTDBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update
Montrouge, France, October 31, 2022 DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that
Read more →DBVTDBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
Montrouge, France, October 3, 2022 DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biop
Read more →DBVT▼ -7.2%on this news
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it receiv
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it received feedback from the U.S. Food and Drug Administration (FD
Read more →DBVTDBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut-Allergic Children Ages 4 to 7 Years DBV has finalized the VITESSE protocol after productive exchanges wit
DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut-Allergic Children Ages 4 to 7 Years DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: D BVT), a clinical-stage biopharmaceutical company, to
Read more →DBVT▲ +13%on this newsshared move
DBV Technologies to Present at Upcoming Investor Conferences
Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Of
Read more →DBVTDBV Technologies Reports Second Quarter 2022 Financial Results
Montrouge, France, August 1, 2022 DBV Technologies Reports Second Quarter 2022 Financial Results DBV closes Q2 with a cash balance of $248M following recent ATM and PIPE offerings DBV continues to practice budget discipline measures; cash used in operating activities decreased
Read more →DBVTDBV Technologies to Participate in Upcoming EAACI 2022 Congress
Montrouge, France, June 28, 2022 DBV Technologies to Participate in Upcoming EAACI 2022 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the hybrid i
Read more →DBVTDBV Technologies to Present at the JMP Securities Life Sciences Conference in New York
Montrouge, France, June 16, 2022 DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tas
Read more →DBVT▲ +79.6%on this news
DBV Technologies Announces Private Placement Financing of $194 Million
Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today announced an aggregate $194 millio
Read more →DBVTDBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers 67.0% of subjects treated with Viaskin Peanut 250 µg met response criteria at 12 months, compared with 33.5% of subjects
Read more →DBVTDBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting
Montrouge, France, May 12, 2022 DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting Shareholders Approved All Proposed Resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharm
Read more →DBVT▲ +5.5%on this news
DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)
Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “Company”), a clinical-stage biotec
Read more →DBVT▲ +7.4%on this newsshared move
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Global Select Market: DBVT) (the Company ), a clinical-stage biotechnological company, today
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Global Select Market: DBVT) (the Company ), a clinical-stage biotechnological company, today announced that it has filed a prospectus supplement with
Read more →DBVT▲ +7.4%on this newsshared move
DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results
Montrouge, France, May 2, 2022 DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results The U.S. Food and Drug Administration (FDA) has granted DBV Technologies a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol The
Read more →DBVTDBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments
Montrouge, France, April 25, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that
Read more →DBVTDBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference
Montrouge, France, March 14, 2022 DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Dr. Pharis Mo
Read more →DBVT▲ +5.3%on this newsshared move
DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document
Montrouge, France, March 9, 2022 DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today an
Read more →DBVT▲ +34.6%on this news
DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates mVP Pivotal Protocol Complete and Ready for Submission to FDA DBV Continues to Engage in Productive Exchanges with FDA Cash Runway Ext
DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates mVP Pivotal Protocol Complete and Ready for Submission to FDA DBV Continues to Engage in Productive Exchanges with FDA Cash Runway Extended into the First Quarter 2023 DBV Technologies S.A.
Read more →DBVTDBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022
Montrouge, France, February 24, 2022 DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced
Read more →DBVTDBV Technologies to Participate in Upcoming AAAAI 2022 Congress
Montrouge, France, February 22, 2022 DBV Technologies to Participate in Upcoming AAAAI 2022 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the Amer
Read more →DBVTDBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Montrouge, France, February 14, 2022 DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Danie
Read more →DBVTDBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference
Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chi
Read more →DBVTDBV Technologies Provides Update on Investigational Viaskin Peanut DBV Technologies S.A. (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced plans to
DBV Technologies Provides Update on Investigational Viaskin DBV Technologies S.A. (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced plans to initiate a new, pivotal Phase 3 clinical study for a modified Via
Read more →DBVTDBV Technologies to Participate in an Upcoming Investor Conference
Montrouge, France, November 24, 2021 DBV Technologies to Participate in an Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the 4th An
Read more →DBVT▲ +7.3%on this news
DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021
Montrouge, France, November 1, 2021 DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new clinical
Read more →DBVTDBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments
Montrouge, France, October 26, 2021 DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reporte
Read more →DBVT▲ +6.9%on this news
DBV Technologies to Participate at Upcoming Investor Conferences
Montrouge, France, August 31, 2021 DBV Technologies to Participate at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that DBV Technologies’ senior manag
Read more →DBVTDBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments
Montrouge, France, August 2, 2021 DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments Business Highlights: Viaskin Peanut US: DBV submitted the protocol for the 6-month adhesion and safety study of the modified patch (STAMP), to the
Read more →DBVTDBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021
Montrouge, France, July 26, 2021 DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced th
Read more →DBVTDBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its Board of Directors
Montrouge, France, May 19, 2021 DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its Board of Directors DBV Technologies (Euronext
Read more →DBVTDBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021
Montrouge, France, May 5, 2021 DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the filing of its
Read more →DBVTCommuniqu de presse Montrouge, France, le 3 mai (7 h 30 CEST) 2021 DBV Technologies annonce ses r sultats financiers du premier trimestre 2021 DBV Technologies S.A. (Euronext : DBV ISIN : FR0010417345 Nasdaq : DBVT), lab
Montrouge, France, le 3 mai (7 h 30 CEST) 2021 DBV Technologies annonce ses r sultats financiers du premier trimestre 2021 DBV Technologies S.A. (Euronext : DBV ISIN : FR0010417345 Nasdaq : DBVT), laboratoire biopharmaceutique fran ais, a annonc aujourd hui ses r sultats finan
Read more →DBVTDBV Technologies Reports Q1 2021 Financial Results
Montrouge, France, May 3, 2021 DBV Technologies Reports Q1 2021 Financial Results DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter of 2021.
Read more →DBVTDBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors
Montrouge, France, April 2, 2021 DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today the provisional appo
Read more →DBVTDBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today
DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today the provisional appointment of Mr. Timothy E. Morris, as
Read more →DBVTDBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting
Montrouge, France, March 26, 2021 DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today
Read more →DBVTDBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document
Montrouge, France, March 17, 2021 DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document The Company also announces that it will enter the SBF 120 Index on Euronext DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Na
Read more →DBVTDBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments DBV Technologies S.A. (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, t
DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments DBV Technologies S.A. (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the year ended Decembe
Read more →DBVTDBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments
Montrouge, France, March 11, 2021 DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financ
Read more →DBVTDBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference
Montrouge, France, March 5, 2021 DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tas
Read more →DBVTDBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results
Montrouge, France, March 3, 2021 DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company
Read more →DBVTDBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021
Montrouge, France, March 1, 2020 DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will hos
Read more →DBVTDBV Technologies to Participate in Upcoming AAAAI 2021 Congress
Montrouge, France, February 24, 2021 DBV Technologies to Participate in Upcoming AAAAI 2021 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the virt
Read more →DBVTDBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer
Montrouge, France, February 22, 2021 DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointm
Read more →DBVTDBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference
Montrouge, France, February 19, 2021 DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel T
Read more →DBVTDBV Technologies Provides Update on Investigational Viaskin Peanut for Children Ages 4-11 Years DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, t
DBV Technologies Provides Update on Investigational Viaskin Peanut for Children Ages 4-11 Years DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the receipt of written responses from the
Read more →DBVTDBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process
Montrouge, France, January 7, 2021 DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, t
Read more →DBVTUNAUDITED INTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (Amounts in thousands of euros) 6/30/2020 12/31/2019 ASSETS Non-current assets Intangible assets 42 43 Right-of-use assets related to leases 18,872
UNAUDITED INTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (Amounts in thousands of euros) 6/30/2020 12/31/2019 ASSETS Non-current assets Intangible assets 42 43 Right-of-use assets related to leases 18,872 20,589 Property, plant,
Read more →DBVTDBV Technologies Announces Leadership Changes
Montrouge, France, November 24, 2020 DBV Technologies Announces Leadership Changes DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Dr. Hugh Sampson has decided to step down from
Read more →DBVTDBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020
Montrouge, France, November 10, 2020 DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020 Meeting also will feature virtual industry symposium on managing food allergies amid the COVID-19 pandemic DBV Technologies (Euron
Read more →DBVTDBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency
Montrouge, France, November 2, 2020 DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage bioph
Read more →DBVTDBV Technologies Reports September 30, 2020 Cash Position
Montrouge, France, October 30, 2020 DBV Technologies Reports September 30, 2020 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported its cash and cash equivalents and number o
Read more →DBVTDBV Technologies to Participate in Multiple September Investor Conferences
Montrouge, France, September 2, 2020 DBV Technologies to Participate in Multiple September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in th
Read more →DBVTDBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years
Montrouge, France, August 4, 2020 DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today
Read more →DBVTSECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2020 Commission File Number: 001-36697 DBV TECHNOLOGIES S.A. (Translation of registrant s nam
Read more →DBVTDBV Technologies Reports First Half 2020 Financial Results
Montrouge, France, July 31, 2020 DBV Technologies Reports First Half 2020 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2020 financial results. The inter
Read more →DBVTDBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology
Montrouge, France, July 7, 2020 DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology PEOPLE is the largest long-term peanut allergy immunotherapy trial to date and showe
Read more →DBVTDBV Technologies Provides Operational and Business Update
Montrouge, France, June 26, 2020 DBV Technologies Provides Operational and Business Update BLA review of Viaskin Peanut for the treatment of peanut allergy in children ages 4-11 years ongoing Company to immediately initiate restructuring plan to extend cash runway while awaiti
Read more →DBVTDBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020
Montrouge, France, June 4, 2020 DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020 Virtual presentations will include data about children with and without multiple food allergies from the pivotal Phase
Read more →DBVTDBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Montrouge, France, June 2, 2020 DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel T
Read more →DBVTDBV Technologies Reports March 31, 2020 Cash Position
Montrouge, France, April 30, 2020 DBV Technologies Reports March 31, 2020 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its cash and cash equivalents and its number of
Read more →DBVTDBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting
Montrouge, France, April 20, 2020 DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting Shareholders approve all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biophar
Read more →DBVTDBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F
Montrouge, France, March 20, 2020 DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced the filing of its 2019 Universal Reg
Read more →DBVTDBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years
Montrouge, France, March 16, 2020 DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years Conference call today, March 16, at 5:00 PM ET / 10:00 PM CET DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-sta
Read more →DBVTDBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update
Montrouge, France, March 4, 2020 DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update Advisory Committee meeting to be held on May 15, 2020 to discuss the Viaskin Peanut Biologics License Application (BLA) with target action date of August 5, 2
Read more →DBVTDBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering
Montrouge, France, March 4, 2020 DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR00104173
Read more →DBVTDBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)
Montrouge, France, March 2, 2020 DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs) DBV Technologies (the “Company”) (Eurone
Read more →DBVTDBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020
Montrouge, France, February 24, 2020 DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that
Read more →DBVTDBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children
Montrouge, France, February 21, 2020 DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmac
Read more →DBVTDBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference
Montrouge, France, February 10, 2020 DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel
Read more →DBVTDBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer
Montrouge, France, February 6, 2020 DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the
Read more →DBVTDBV Technologies Announces Closing of Global Offering
Montrouge, France, February 4, 2020 DBV Technologies Announces Closing of Global Offering DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery o
Read more →DBVTDBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position DBV Technologies (the Company ) (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DB
Read more →DBVTDBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
Montrouge, France, January 30, 2020 DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock
Read more →DBVTCONTENT I INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 1 II MANAGEMENT DISCUSSION & ANALYSES 25 III INFORMATION REGARDING RELATIONSHIPS WITH RELATED PARTIES 30 IV RISK
I INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 1 II MANAGEMENT DISCUSSION & ANALYSES 25 III INFORMATION REGARDING RELATIONSHIPS WITH RELATED PARTIES 30 IV RISK FACTORS 31 I CONDENSED CONSOLIDATED FINANCIAL STATEMENT
Read more →DBVTUnlocking the Powerful Immune Properties of the Skin to Offer Innovative Treatments to Patients January 2020 Safe Harbor This presentation contains forward looking statements including, but not limited to, statements con
Offer Innovative Treatments to Patients January 2020Exhibit 99.1 Unlocking the Powerful Immune Properties of the Skin to Offer Innovative Treatments to Patients January 2020 Safe Harbor This presentation contains forward looking statements including, but not limited to, stateme
Read more →DBVTDBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy Patients demonstrated durable, long-term clinical benefi
DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment Low discontin
Read more →DBVTDBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer
Montrouge, France, January 2, 2020 DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment o
Read more →DBVTDBV Technologies to Present at the Stifel 2019 Healthcare Conference
Montrouge, France, November 5, 2019 DBV Technologies to Present at the Stifel 2019 Healthcare Conference DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Kevin Trapp, Chief Comme
Read more →DBVTDBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019
Montrouge, France, October 24, 2019 DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019 New analysis evaluates quality of life in patients receiving investigational Viaskin Peanut DBV Technologies (Euronext: DBV
Read more →DBVTDBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)
Montrouge, France, October 10, 2019 DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs) DBV Technologies (the “Company”) (Eurone
Read more →DBVTDBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharma
Read more →DBVTDBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position
Montrouge, France, October 8, 2019 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position DBV Technologies (the “Company”) (Euronext: DBV – ISIN
Read more →DBVTDBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy
Montrouge, France, October 4, 2019 DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening c
Read more →DBVTCONTENT I FIRST HALF 2019 INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 2 II MANAGEMENT DISCUSSION & ANALYSES 24 III INFORMATION REGARDING RELATIONSHIPS WITH RELATED PARTIES 29 IV RISK FACTORS 30 1 I FIRST HALF OF
I FIRST HALF 2019 INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 2 II MANAGEMENT DISCUSSION & ANALYSES 24 III INFORMATION REGARDING RELATIONSHIPS WITH RELATED PARTIES 29 IV RISK FACTORS 30 I FIRST HALF OF 2019 CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INTERIM
Read more →DBVTDBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy
Montrouge, France, August 7, 2019 DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-sta
Read more →DBVTDBV Technologies Reports First Half 2019 Financial Results
Montrouge, France, August 1, 2019 DBV Technologies Reports First Half 2019 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2019 financial results. The inte
Read more →DBVTDBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer
Montrouge, France, June 26, 2019 DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer Dr. Mohideen brings extensive experience in clinical drug development Dr. Hugh Sampson to continue serving as Chief Scientific Officer DBV Technologies (
Read more →DBVTDBV Technologies to Attend Upcoming Investor Conferences
Montrouge, France, June 3, 2019 DBV Technologies to Attend Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that members of its management team will prese
Read more →DBVTDBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019
Montrouge, France, June 1, 2019 DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 Data presented highlights potential long-term benefit of Viaskin® Peanut DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical
Read more →DBVTDBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors
Montrouge, France, May 24, 2019 DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors Shareholders approve all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR001
Read more →DBVTDBV Technologies Announces Departure of Deputy CEO David Schilansky
Montrouge, France, May 14, 2019 DBV Technologies Announces Departure of Deputy CEO David Schilansky DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that its Deputy Chief Executive Off
Read more →DBVTDBV Technologies Reports March 31, 2019 Cash Position
Montrouge, France, April 30, 2019 DBV Technologies Reports March 31, 2019 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its cash and cash equivalents as of March 31, 2
Read more →DBVTDBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS)
Montrouge, France, April 5, 2019 DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS) DBV Technologies (the “Company”)
Read more →DBVTDBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
Montrouge, France, April 4, 2019 DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Marke
Read more →DBVTDBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares DBV Technologies (the Company ) (Euronext: DBV ISIN: FR0010417345 Nasdaq Stoc
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares DBV Technologies (the Company ) (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa
Read more →DBVTIndex to Financial Statements Page Annual Financial Statements for the Years Ended
Index to Financial Statements Page Annual Financial Statements for the Years Ended December 31, 2016, 2017 and 2018: Report of Deloitte & Associ s, Independent Registered Public Accounting Firm 2 Report of Deloitte & Associ s, Independent Registered Public Accounting F
Read more →DBVT(DBVT) DBV Technologies S.A. Bronstein, Gewirtz & Grossman, LLC Class Action Update and Deadline - March 18, 2019
NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against DBV Technologies S.A. (“DBV” or the “Company”) (NASDAQ: DBVT) and certain of its officers, on behalf of sha
Read more →DBVTDBV MARCH 18 DEADLINE: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against DBV Technologies S.A. – DBVT
NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of DBV Technologies S.A. (NASDAQ: DBVT) from February 14, 2018 through December 19, 2018, inclusive (the “Class Period”). The
Read more →DBVTDBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors
Montrouge, France, March 5, 2019 DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors Mr. de Rosen to succeed DBV’s co-founder, Dr. Pierre-Henri Benhamou, who will retire from the Board of Directors and join Scientific Ad
Read more →DBVTDBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update
Montrouge, France, March 5, 2019 DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced full year 20
Read more →DBVTDBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association Viaskin Peanut is the first
DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association Viaskin Peanut is the first epicutaneous immunotherapy (EPIT) in development that lev
Read more →DBVTDBVT MARCH 18th DEADLINE: Rosen Law Firm Files Securities Class Action Lawsuit Against DBV Technologies S.A. – DBVT
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of DBV Technologies S.A. (NASDAQ: DBVT) from February 14, 2018 through December 19, 2018, inclusi
Read more →DBVTDBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age
Montrouge, France, February 13, 2019 DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age Progress made to date to enable BLA resubmission in Q3 2019 Company to hold conference call today, Fe
Read more →DBVTDBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company
Monthly information regarding the total number of voting rights and total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Tota
Read more →DBVTDBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019
DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019 Novel immunotherapy based on Viaskin technology highlighted as a potential treatment for food-allergic patients DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clin
Read more →DBVTDBV TECHNOLOGIES S.A. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against DBV Technologies S.A.
NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of investors that acquired DBV Technologies S.A. (“DBV Technolo
Read more →DBVTDBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference
DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer,
Read more →DBVTDBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Un
Read more →DBVTDBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company
Monthly information regarding the total number of voting rights and total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Tota
Read more →DBVTSafe Harbor This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or success of DBV's clinical trials; its ability to successfully gain regulatory approval
The Epicutaneous Immunotherapy Company January 2019 Genoskin Exhibit 99.1 Safe Harbor This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or success of DBV's clinical trials; its ability to successfully gain re
Read more →DBVTDBV Technologies Expands and Strengthens Leadership Team
Accessibility: Skip TopNav DBV Technologies Expands and Strengthens Leadership Team January 03, 2019 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Expands and Strengthens Leadership Team Key medical, manufacturing and regulatory leadership changes an
Read more →DBVTDBV Technologies: DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age
Accessibility: Skip TopNav DBV Technologies: DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age December 19, 2018 17:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Provides Update on Viaskin Peanut for Children Four to
Read more →DBVTUNAUDITED INTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (thousands of euros) 6/30/2018 12/31/2017 ASSETS Non-current assets Intangible assets 26 123 Property, plant, and equipment 17,418 17,808 Other non
UNAUDITED INTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (thousands of euros) 6/30/2018 12/31/2017 ASSETS Non-current assets Intangible assets 26 123 Property, plant, and equipment 17,418 17,808 Other non-current financial assets
Read more →DBVTDBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018
Accessibility: Skip TopNav DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018 December 12, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Highlights Data Supporting In
Read more →DBVTDBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children
Accessibility: Skip TopNav DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children November 20, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Presents Data at ACAAI 2018 on Inve
Read more →DBVTDBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting
Accessibility: Skip TopNav DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting November 09, 2018 01:31 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Prese
Read more →DBVTDBV Technologies Reports September 30, 2018 Cash Position
DBV Technologies Reports September 30, 2018 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and cash equivalents as of September 30, 2018. Cash and cash equivalents: Cash and cash equivalents as of Septem
Read more →DBVTDBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers
Accessibility: Skip TopNav DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers October 26, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allerg
Read more →DBVTDBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration
Accessibility: Skip TopNav DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration October 22, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Submission of Biolog
Read more →DBVTDBV Technologies to Present at the Cantor Global Healthcare Conference
Accessibility: Skip TopNav DBV Technologies to Present at the Cantor Global Healthcare Conference September 25, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present at the Cantor Global Healthcare Conference DBV Technologies (Euronext: DBV -
Read more →DBVTDBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers
Accessibility: Skip TopNav DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers September 12, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Positive DSMB Review of Part A of Phase III
Read more →DBVTDBV Technologies : Reports First Half 2018 Financial Results
Accessibility: Skip TopNav DBV Technologies : Reports First Half 2018 Financial Results September 07, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports First Half 2018 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 -
Read more →DBVTDBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the ECI
Accessibility: Skip TopNav DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the ECI September 05, 2018 01:30 ET DBV Technologies S.A. DBV Te
Read more →DBVTDBV Technologies Reports June 30, 2018 Cash Position
DBV Technologies Reports June 30, 2018 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and cash equivalents as of June 30, 2018. Cash and cash equivalents: Cash and cash equivalents as of June 30, 2018, w
Read more →DBVTDBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF
Accessibility: Skip TopNav DBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF July 13, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Od
Read more →DBVTDBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company ...
Accessibility: Skip TopNav DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company ... June 26, 2018 11:44 ET DBV Technologies S.A. DBV Technologies S.A. Monthly information regarding the total number of vo
Read more →DBVTDBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel
Accessibility: Skip TopNav DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel June 22, 2018 16:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Techno
Read more →DBVTDBV Technologies: Ordinary and Extraordinary General Meeting of June 22, 2018 - Procedures for Obtaining Preparatory Documents for the General Meeting
Accessibility: Skip TopNav DBV Technologies: Ordinary and Extraordinary General Meeting of June 22, 2018 - Procedures for Obtaining Preparatory Documents for the General Meeting June 01, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. Ordinary and Extraordinary Gen
Read more →DBVTDBV Technologies : Information regarding the total number of voting rights and total number of shares of the Company on May 18th, 2018
Accessibility: Skip TopNav DBV Technologies : Information regarding the total number of voting rights and total number of shares of the Company on May 18th, 2018 May 29, 2018 13:02 ET DBV Technologies S.A. DBV Technologies S.A. Monthly information regarding the total number
Read more →DBVTDBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018
Accessibility: Skip TopNav DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018 May 29, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Shows Commitment to the Development of Treatments for Food Allerg
Read more →DBVTDBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors
Accessibility: Skip TopNav DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors May 16, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors DBV Technolog
Read more →DBVTDBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week
Accessibility: Skip TopNav DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week May 14, 2018 08:31 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Partners with FARE to
Read more →DBVTDBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting
Accessibility: Skip TopNav DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting May 08, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Me
Read more →DBVTDBV Technologies Reports March 31, 2018 Cash Position
DBV Technologies Reports March 31, 2018 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and cash equivalents as of March 31, 2018. Cash and cash equivalents: Cash and cash equivalents as of March 31, 2018
Read more →DBVTDBV Technologies to Attend the 11th Kempen Life Sciences Conference
Accessibility: Skip TopNav DBV Technologies to Attend the 11th Kempen Life Sciences Conference April 03, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Attend the 11th Kempen Life Sciences Conference DBV Technologies (Euronext: DBV - ISIN: FR0
Read more →DBVTDBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering
Accessibility: Skip TopNav DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering March 26, 2018 16:01 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Closing of Underwriters' Option to Purchase A
Read more →DBVTDBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters Option to Purchase Additional Shares DBV Technologies (the Company ) (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a
DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters Option to Purchase DBV Technologies (the Company ) (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the closing of an
Read more →DBVTDBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
Accessibility: Skip TopNav DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares March 21, 2018 03:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Annou
Read more →DBVTDBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares
Accessibility: Skip TopNav DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares March 20, 2018 16:01 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces the Launch
Read more →DBVTDBV Technologies Reports Full Year 2017 Financial Results
Accessibility: Skip TopNav DBV Technologies Reports Full Year 2017 Financial Results March 14, 2018 02:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports Full Year 2017 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq S
Read more →DBVTDBV Technologies to Present at the Barclays Global Healthcare Conference
Accessibility: Skip TopNav DBV Technologies to Present at the Barclays Global Healthcare Conference March 07, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present at the Barclays Global Healthcare Conference DBV Technologies (Euronext: DBV -
Read more →DBVTDBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients
Accessibility: Skip TopNav DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients February 26, 2018 17:05 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-A
Read more →DBVTDBV Technologies Reports December 31, 2017 Cash Position
DBV Technologies Reports December 31, 2017 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and cash equivalents as of December 31, 2017. Cash and cash equivalents Cash and cash equivalents as of December
Read more →DBVTDBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut
Accessibility: Skip TopNav DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut February 14, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut DBV Technologies (Euronext
Read more →DBVTDBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference
Accessibility: Skip TopNav DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference January 03, 2018 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present at the 36 th Annual J.P. Morgan Healthcare Conference DBV Technologi
Read more →DBVTDBV Technologies :Monthly information regarding the total number of voting rights and total number of shares of the Company
Accessibility: Skip TopNav DBV Technologies :Monthly information regarding the total number of voting rights and total number of shares of the Company December 22, 2017 06:30 ET DBV Technologies S.A. DBV Technologies S.A. Monthly information regarding the total number of vot
Read more →DBVTDBV Technologies CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Recognized for His Lasting Impact on the Food Allergy Community and Research Advancement by FARE (Food Allergy Research & E...
Accessibility: Skip TopNav DBV Technologies CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Recognized for His Lasting Impact on the Food Allergy Community and Research Advancement by FARE (Food Allergy Research & E... December 04, 2017 01:30 ET DBV Technologies S.A.
Read more →DBVTDBV Technologies to Attend Citi's 2017 Global Healthcare Conference
Accessibility: Skip TopNav DBV Technologies to Attend Citi's 2017 Global Healthcare Conference November 28, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Attend Citi's 2017 Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN:
Read more →DBVTDBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients
Accessibility: Skip TopNav DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients November 20, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announce
Read more →DBVTUNAUDITED INTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (Amounts in thousands of euros) 6/30/2017 12/31/2016 ASSETS Non-current assets Intangible assets 156 96 Property, plant, and equipment 15,400 12,48
UNAUDITED INTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (Amounts in thousands of euros) 6/30/2017 12/31/2016 ASSETS Non-current assets Intangible assets 156 96 Property, plant, and equipment 15,400 12,482 Other non-current finan
Read more →DBVTDBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association
Accessibility: Skip TopNav DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association November 14, 2017 11:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technol
Read more →DBVTDBV Technologies Reports September 30, 2017 Cash Position
DBV Technologies Reports September 30, 2017 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and cash equivalents as of September 30, 2017. Cash and cash equivalents Cash and cash equivalents as of Septemb
Read more →DBVTDBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age
Accessibility: Skip TopNav DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age October 20, 2017 17:15 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Topline Results of Phase II
Read more →DBVTDBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut
Accessibility: Skip TopNav DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut October 12, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Pea
Read more →DBVTDBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut
Accessibility: Skip TopNav DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut August 29, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Completion of Enrollment in Phase III Extension Study
Read more →DBVTDBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age
Accessibility: Skip TopNav DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age August 02, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Initiates Phase III Study of Viaskin Peanut in
Read more →DBVTDBV Technologies Reports First Half 2017 Financial Results
Accessibility: Skip TopNav DBV Technologies Reports First Half 2017 Financial Results July 28, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports First Half 2017 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq
Read more →DBVTDBV Technologies Highlights Poster Presentations on EPIT at the 2017 EAACI Congress
Accessibility: Skip TopNav DBV Technologies Highlights Poster Presentations on EPIT® at the 2017 EAACI Congress June 17, 2017 02:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Highlights Poster Presentations on EPIT ® at the 2017 EAACI Congress DBV Techn
Read more →DBVTDBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting
Accessibility: Skip TopNav DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting June 15, 2017 16:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Sharehol
Read more →DBVTDBV Technologies Announces Appointment of Julie O'Neill to Board of Directors
Accessibility: Skip TopNav DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors June 15, 2017 16:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors DBV Technologies (Eurone
Read more →DBVTDBV TECHNOLOGIES Limited company with share capital of 2,466,883.80 Registered office: 177-181 avenue Pierre Brossolette 92120 Montrouge. Nanterre Trade and Companies Register (RCS) 441 772 522. NOTICE OF MEETING The sha
company with share capital of 2,466,883.80 Registered office: 177-181 avenue Pierre Brossolette 92120 Montrouge. Nanterre Trade and Companies Register (RCS) 441 772 522. shareholders of the Company are hereby invited to attend the Combined Ordinary and Extraordinary General Me
Read more →DBVTDBV Technologies : Ordinary and Extraordinary General Meeting of June 15, 2017 Procedures for Obtaining Preparatory Documents for the General Meeting
Accessibility: Skip TopNav DBV Technologies : Ordinary and Extraordinary General Meeting of June 15, 2017 Procedures for Obtaining Preparatory Documents for the General Meeting May 24, 2017 16:30 ET DBV Technologies S.A. DBV Technologies S.A. Ordinary and Extraordinary Gener
Read more →DBVTDBV Technologies Highlights Research Presentation of EPIT for the Treatment of Crohn's Disease at Digestive Disease Week 2017
Accessibility: Skip TopNav DBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn's Disease at Digestive Disease Week 2017 May 08, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Highlights Research Presentation of EP
Read more →DBVTDBV Technologies Reports March 31, 2017 Cash Position
DBV Technologies Reports March 31, 2017 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and cash equivalents as of March 31, 2017. Cash and cash equivalents DBV's cash and cash equivalents amounted to €22
Read more →DBVTDBV Technologies to Attend the 10th Kempen Life Sciences Conference
Accessibility: Skip TopNav DBV Technologies to Attend the 10th Kempen Life Sciences Conference April 05, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Attend the 10th Kempen Life Sciences Conference DBV Technologies (Euronext: DBV - ISIN: FR0
Read more →DBVTDBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination
Accessibility: Skip TopNav DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination March 30, 2017 16:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies, BioNet-Asia and Genev
Read more →DBVTDBV Technologies Reports Full Year 2016 Financial Results
Accessibility: Skip TopNav DBV Technologies Reports Full Year 2016 Financial Results March 15, 2017 02:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports Full Year 2016 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq
Read more →DBVTDBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children
Accessibility: Skip TopNav DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children March 10, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Completion of Enrollment of the REALISE Study in Pea
Read more →DBVTDBV Technologies :Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children
Accessibility: Skip TopNav DBV Technologies :Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children March 05, 2017 15:45 ET DBV Technologies S.A. DBV Techn
Read more →DBVTDBV Technologies Reports December 31, 2016 Cash Position
DBV Technologies Reports December 31, 2016 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced its cash and cash equivalents as of December 31, 2016. Full year 2016 financial results will be announced on March 15, 201
Read more →DBVTDBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis
Accessibility: Skip TopNav DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis February 03, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Complet
Read more →DBVTDBV Technologies to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
Accessibility: Skip TopNav DBV Technologies to Present at the LEERINK Partners 6th Annual Global Healthcare Conference January 26, 2017 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present at the LEERINK Partners 6th Annual Global Healthcare Confe
Read more →DBVTDBV Technologies Announces Financial Calendar 2017
DBV Technologies Announces Financial Calendar 2017 DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced its 2017 financial calendar[1] : February 20, 2017 - cash position December 31, 2016 March 15, 2017 - full-year 2016 results A
Read more →DBVTDBV Technologies presents its Half-year Statement of the Liquidity Contract
Accessibility: Skip TopNav DBV Technologies presents its Half-year Statement of the Liquidity Contract January 04, 2017 11:56 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Presents its Half-year Statement of the Liquidity Contract As per the liquidity con
Read more →DBVTUNAUDITED INTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (Amounts in thousands of euros) 6/30/2016 12/31/2015 ASSETS Non-Current assets Intangible assets 228 94 Property, plant, and equipment 10,305 5,581
UNAUDITED INTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (Amounts in thousands of euros) 6/30/2016 12/31/2015 ASSETS Non-Current assets Intangible assets 228 94 Property, plant, and equipment 10,305 5,581 Other non-current financ
Read more →DBVTDBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis
Accessibility: Skip TopNav DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis November 17, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Techn
Read more →DBVTDBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting
Accessibility: Skip TopNav DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting November 11, 2016 19:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Poster Presentations at the 20
Read more →DBVTDBV Technologies Completes Enrollment of Phase II Study of Viaskin Milk for the Treatment of Milk Allergic Patients
Accessibility: Skip TopNav DBV Technologies Completes Enrollment of Phase II Study of Viaskin Milk for the Treatment of Milk Allergic Patients November 08, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Completes Enrollment of Phase II Study of Vi
Read more →DBVTDBV Technologies Reports September 30, 2016 Cash Position
DBV Technologies Reports September 30, 2016 Cash Position DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced its cash and cash equivalents as of September 30, 2016. Cash and cash equivalents DBV's cash and cash equivalents amoun
Read more →DBVTDBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology
Accessibility: Skip TopNav DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology October 26, 2016 16:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technolo
Read more →DBVTDBV Technologies: Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut
Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut Favorable safety and high compliance were reported in OLFUS, consistent with prior results A vast majority of children continue to respond to treatment
Read more →DBVTDBV Technologies : Monthly information regarding the total number of voting rights andtotal number of shares of the Company
Accessibility: Skip TopNav DBV Technologies : Monthly information regarding the total number of voting rights andtotal number of shares of the Company October 17, 2016 06:31 ET DBV Technologies S.A. DBV Technologies S.A. Monthly information regarding the total number of voti
Read more →DBVTDBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow's Milk Protein Allergy
Accessibility: Skip TopNav DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow's Milk Protein Allergy September 21, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Receives FDA Fast Track Designation for V
Read more →DBVTDBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination
Accessibility: Skip TopNav DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination September 06, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies, BioNet-Asia and the
Read more →DBVTDBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy
Accessibility: Skip TopNav DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy August 01, 2016 16:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Expansion of Clinical Program of Viaskin
Read more →DBVTDBV Technologies Reports Interim Financial Results for the First Half of 2016
Accessibility: Skip TopNav DBV Technologies Reports Interim Financial Results for the First Half of 2016 July 28, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports Interim Financial Results for the First Half of 2016 DBV Technologies, (Euro
Read more →DBVTDBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer
MONTROUGE, France, July 5, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the appointment of Lucia Septi n, M.D., as Chief Medical Officer. Dr. Septi
Read more →DBVTDBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children
Accessibility: Skip TopNav DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children June 27, 2016 16:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Completion
Read more →DBVTDBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere
Montrouge, France, June 21, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the appointment of Claire Giraut and Ma lys Ferrere to its Board of Direct
Read more →DBVTDBV Technologies Announced Results of its 2016 Annual Meeting of Shareholders
Accessibility: Skip TopNav DBV Technologies Announced Results of its 2016 Annual Meeting of Shareholders June 21, 2016 16:31 ET DBV Technologies S.A. DBV Technologies S.A. DBV Announced Results of its 2016 Annual Meeting of Shareholders Adoption of all resolutions submitted
Read more →DBVTDBV Technologies to Present at the JMP Securities Life Sciences Conference
Accessibility: Skip TopNav DBV Technologies to Present at the JMP Securities Life Sciences Conference June 16, 2016 16:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present at the JMP Securities Life Sciences Conference DBV Technologies, (Euronext: D
Read more →DBVTDBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin(r) Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression
Early-Stage Proprietary Model Suggests that Serum Biomarkers may help Monitor Treatment Progression with Viaskin Peanut Additionally, Another DBV Data Presentation is Chosen as "Best of Poster Discussion Session" by EAACI Congress VIENNA, Austria, June 15, 2016 (GLOBE NEWSWIRE)
Read more →DBVTDBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT(r) Provides Sustained Protection Against Anaphylaxis
DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT Provides Sustained Protection Against Anaphylaxis MONTROUGE, France, June 13, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical
Read more →DBVTDBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board
Accessibility: Skip TopNav DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board June 07, 2016 16:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Appointment of Leading Japane
Read more →DBVTDBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies
Accessibility: Skip TopNav DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies June 01, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in
Read more →DBVTDBV Technologies and Nestle Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy
BAGNEUX, France, May 31, 2016 (GLOBE NEWSWIRE) -- DBV Technologies and Nestl Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy Collaboration will support DBV's Mission to Develop Transformational Product Candidates
Read more →DBVTDBV Technologies: Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly
Accessibility: Skip TopNav DBV Technologies: Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly May 30, 2016 16:30 ET DBV Technologies S.A. DBV Technologies S.A. Mixed General Assembly of June 21, 2016 Procedures for obta
Read more →DBVTDBV Technologies Reports March 31, 2016 Cash Position
Accessibility: Skip TopNav DBV Technologies Reports March 31, 2016 Cash Position April 29, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports March 31, 2016 Cash Position DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock M
Read more →DBVTDBV Technologies Announces Filing of 2015 "Document de Reference" and 2015 Annual Report on Form 20-F
MONTROUGE, France, April 28, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the filing of its 2015 Annual Report "Document de R f rence" for the year
Read more →DBVTDBV Technologies Announces Publication of Experimental Data on Targeted Regulatory T Cell Induction during Epicutaneous Immunotherapy
Accessibility: Skip TopNav DBV Technologies Announces Publication of Experimental Data on Targeted Regulatory T Cell Induction during Epicutaneous Immunotherapy April 11, 2016 16:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Publication of Expe
Read more →DBVTDBV Technologies Reports Full Year 2015 Financial Results
Accessibility: Skip TopNav DBV Technologies Reports Full Year 2015 Financial Results April 07, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports Full Year 2015 Financial Results DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq
Read more →DBVTDBV Technologies: Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance
Accessibility: Skip TopNav DBV Technologies: Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance March 06, 2016 17:00 ET DBV Technologies S.A. DBV Technologies S.A. Additiona
Read more →DBVTDBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin(R) Peanut Safety and Efficacy
Results Presented at the AAAAI Meeting Showed CoFAR6 Met Primary Endpoint, With a Strong Response Observed in Children Early Mechanistic Results are In-Line with DBV's Preclinical Findings MONTROUGE, France, March 4, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - IS
Read more →DBVTDBV Technologies to Attend Upcoming Investor Conferences and Events
Accessibility: Skip TopNav DBV Technologies to Attend Upcoming Investor Conferences and Events March 01, 2016 16:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Attend Upcoming Investor Conferences and Events DBV Technologies, (Euronext: DBV - ISIN: FR
Read more →DBVTDBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety and Tolerability of Viaskin(R) Peanut
MONTROUGE, France, Feb. 25, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the publication of results from a Phase Ib trial showing that Viaskin Pean
Read more →DBVTDBV Technologies Reports December 31, 2015, Cash Position
Accessibility: Skip TopNav DBV Technologies Reports December 31, 2015, Cash Position February 15, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports December 31, 2015, Cash Position DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nas
Read more →DBVTDBV Technologies to Present New Data at the 2016 AAAAI Annual Meeting
Accessibility: Skip TopNav DBV Technologies to Present New Data at the 2016 AAAAI Annual Meeting February 10, 2016 08:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present New Data at the 2016 AAAAI Annual Meeting 2-Year Follow-Up of Clinical Data Fu
Read more →DBVTDBV Technologies to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Accessibility: Skip TopNav DBV Technologies to Present at the LEERINK Partners 5th Annual Global Healthcare Conference February 08, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present at the LEERINK Partners 5 th Annual Global Healthcare Con
Read more →DBVTDBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North America
Accessibility: Skip TopNav DBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North America January 26, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Proudly Welcomes Edward Jordan as Senior Vice Presi
Read more →DBVTDBV Technologies Announces 2016 Financial Calendar
Accessibility: Skip TopNav DBV Technologies Announces 2016 Financial Calendar January 08, 2016 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces 2016 Financial Calendar DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
Read more →DBVTINTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (Amounts in euros) 06/30/2015 12/31/2014 ASSETS Non-Current assets Intangible assets 48,507 28,835 Property, plant, and equipment 2,291,170 2,224,928 Other n
INTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION 06/30/2015 12/31/2014 ASSETS Non-Current assets Intangible assets 48,507 28,835 Property, plant, and equipment 2,291,170 2,224,928 Other non-current financial assets 1,995,787 1,
Read more →DBVTDBV Technologies Presents its Half-year Statement of the Liquidity Contract
Accessibility: Skip TopNav DBV Technologies Presents its Half-year Statement of the Liquidity Contract January 07, 2016 09:52 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Presents its Half-year Statement of the Liquidity Contract As per the liquidity con
Read more →DBVTDBV Technologies: First Experimental Results for the Treatment of Colitis with Viaskin(r) will be presented at the Crohn's & Colitis Foundation of America's 2015 Advances in IBD Conference (AIBD)
BAGNEUX, France, Dec. 10, 2015 (GLOBE NEWSWIRE) -- First Experimental Results for the Treatment of Colitis with Viaskin will be presented at the Crohn's & Colitis Foundation of America's 2015 Advances in IBD Conference (AIBD) DBV Technologies (Euronext: DBV - ISIN: FR0010417345
Read more →DBVTDBV Technologies Announces Initiation of Phase III Study of Viaskin(r) Peanut for the Treatment of Peanut Allergic Children
BAGNEUX, France, Dec. 7, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the initiation of a pivotal Phase III study designed to evaluate the safety a
Read more →DBVTDBV Technologies to Present Preclinical Data on its Viaskin(R) Technology for RSV Vaccination at the 2015 RSV Vaccines for the World Meeting
BAGNEUX, France, Nov. 18, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today presented new preclinical data on the use of its Epicutaneous Immunotherapy (EPIT ), V
Read more →DBVTDBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis
Accessibility: Skip TopNav DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis November 12, 2015 17:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Enrollment of First Patient in Phase I
Read more →DBVTDBV Technologies Reports Interim Financial Results for the third quarter of 2015
Accessibility: Skip TopNav DBV Technologies Reports Interim Financial Results for the third quarter of 2015 November 03, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports Interim Financial Results for the third quarter of 2015 DBV Technologi
Read more →DBVTDBV Technologies Announces the Appointment of Michael J. Goller to its Board of Directors
Accessibility: Skip TopNav DBV Technologies Announces the Appointment of Michael J. Goller to its Board of Directors October 21, 2015 18:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces the Appointment of Michael J. Goller to its Board of Director
Read more →DBVTDBV Technologies Announces First Patient Enrolled in Phase II Study of Viaskin Milk
Accessibility: Skip TopNav DBV Technologies Announces First Patient Enrolled in Phase II Study of Viaskin Milk October 14, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces First Patient Enrolled in Phase II Study of Viaskin Milk No safety
Read more →DBVTDBV Technologies To Enter SBF 120 Index
Accessibility: Skip TopNav DBV Technologies To Enter SBF 120 Index September 11, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies To Enter SBF 120 Index DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-
Read more →DBVTDBV Technologies : Invited to Present at the Royal Society of Medicine 11th Medical Innovations Summit
Accessibility: Skip TopNav DBV Technologies : Invited to Present at the Royal Society of Medicine 11th Medical Innovations Summit September 08, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Invited to Present at the Royal Society of Medicine 11 t
Read more →DBVTDBV Technologies : DBV Technologies' Extraordinary General Assembly on September 21, 2015
Accessibility: Skip TopNav DBV Technologies : DBV Technologies' Extraordinary General Assembly on September 21, 2015 September 01, 2015 08:11 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies' Extraordinary General Assembly on September 21, 2015 DBV Technologi
Read more →DBVTREPORT BY THE BOARD OF DIRECTORS NOTICE OF EXTRAORDINARY GENERAL MEETING ON SEPTEMBER 21, 2015 Dear Shareholders, During its
REPORT BY THE BOARD OF DIRECTORS NOTICE OF EXTRAORDINARY GENERAL MEETING ON SEPTEMBER 21, 2015 During its July 24, 2015 meeting, your Board of Directors decided to call an Extraordinary General Meeting, in accordance with bylaws and government regulations, to ask you to author
Read more →DBVTDBV Technologies Reports Interim Financial Results for the First Half of 2015
Accessibility: Skip TopNav DBV Technologies Reports Interim Financial Results for the First Half of 2015 July 27, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports Interim Financial Results for the First Half of 2015 DBV Technologies, (Euro
Read more →DBVTDBV Technologies : Announces Closing of $281.5 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Accessibility: Skip TopNav DBV Technologies : Announces Closing of $281.5 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares July 20, 2015 16:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies A
Read more →DBVTDBV Technologies Announces Pricing of Underwritten Public Offering of Ordinary Shares
Accessibility: Skip TopNav DBV Technologies Announces Pricing of Underwritten Public Offering of Ordinary Shares July 15, 2015 02:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Pricing of Underwritten Public Offering of Ordinary Shares DBV Tech
Read more →DBVTDBV Technologies Announces Launch of Proposed Underwritten Public Offering of Ordinary Shares
Accessibility: Skip TopNav DBV Technologies Announces Launch of Proposed Underwritten Public Offering of Ordinary Shares July 14, 2015 16:05 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Launch of Proposed Underwritten Public Offering of Ordinary
Read more →DBVTDBV Technologies : IND Acceptance from FDA for a proof-of-concept trial using Viaskin(r) Milk in Milk-Induced Eosinophilic Esophagitis in Children
BAGNEUX, France, July 8, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted an investigator
Read more →DBVTDBV Technologies announces the filing of a registration statement on Form F-1 in view of an offering of new shares in the form of American Depositary Shares, and the filing of its Reference Document
Accessibility: Skip TopNav DBV Technologies announces the filing of a registration statement on Form F-1 in view of an offering of new shares in the form of American Depositary Shares, and the filing of its Reference Document July 02, 2015 17:30 ET DBV Technologies S.A. DBV T
Read more →DBVTDBV Technologies Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin(R) Milk in Pediatric Cow's Milk Allergy
DSMB expressed no safety concerns and recommended that the study continue as planned Initiation of Part B expected in the second half of 2015 pending consultation with regulatory agencies BAGNEUX, France, June 30, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN:
Read more →DBVTDBV Technologies Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer
Accessibility: Skip TopNav DBV Technologies Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer June 26, 2015 01:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer DBV Technologies (Eur
Read more →DBVTDBV Technologies' June 23, 2015 Combined Shareholders' Meeting
Accessibility: Skip TopNav DBV Technologies' June 23, 2015 Combined Shareholders' Meeting June 23, 2015 05:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies' June 23, 2015 Combined Shareholders' Meeting Adoption of all resolutions submitted to the vote of S
Read more →DBVTDBV Technologies Confirms Planned Initiation of Viaskin(R) Peanut Global Phase III Clinical Trial in Children Following End-of-Phase II Meeting with FDA and PIP approval by EMA
Phase III clinical trial in children expected to begin in Q4 2015 Comprehensive development plan for Viaskin Peanut announced Bagneux, France, June 22, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage s
Read more →DBVTKey Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine PARIS, BANGKOK and GENEVA, 10 June 2015 - DBV Technolo
Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine PARIS, BANGKOK and GENEVA, 10 June 2015 - DBV Technologies Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Mark
Read more →DBVTDBV Technologies Presents Clinical and Scientific Data at the EAACI Congress
Accessibility: Skip TopNav DBV Technologies Presents Clinical and Scientific Data at the EAACI Congress June 08, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Presents Clinical and Scientific Data at the EAACI Congress Data presented on VIPES co
Read more →DBVTDBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin(r) Peanut for the Treatment of Peanut Allergic Children
BAGNEUX, France, June 4, 2015 (GLOBE NEWSWIRE) -- DBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin Peanut for the Treatment of Peanut Allergic Children Acceptance of this Paediatric Investigation Plan (P
Read more →DBVTDBV Technologies: Mixed General Assembly of June 23, 2015
BAGNEUX, France, June 2, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - NASDAQ: DBVT), French biopharmaceutical company, announces that it will hold its Mixed General Assembly on June 23, 2015 at 9:00 a.m. at the company headquarters, 80/84 rue d
Read more →DBVTBagneux, France
Bagneux, France, May 20, 2015 the Resolutions Proposed to the Mixed General Assembly of DBV DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announces that the resolutions proposed for it
Read more →DBVTDBV Technologies : Publication of the Resolutions Proposed to the Mixed General Assembly of DBV
Accessibility: Skip TopNav DBV Technologies : Publication of the Resolutions Proposed to the Mixed General Assembly of DBV May 20, 2015 17:30 ET DBV Technologies S.A. DBV Technologies S.A. Publication of the Resolutions Proposed to the Mixed General Assembly of DBV DBV Tec
Read more →DBVTDBV Technologies : Topline Financial Results for First Three Months of 2015
Accessibility: Skip TopNav DBV Technologies : Topline Financial Results for First Three Months of 2015 April 29, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. Topline Financial Results for First Three Months of 2015 DBV Technologies, (Euronext: DBV - ISIN: FR00
Read more →DBVTDBV Technologies Selected to Enter Euronext's Tech 40 Label
Accessibility: Skip TopNav DBV Technologies Selected to Enter Euronext's Tech 40 Label April 28, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Selected to Enter Euronext's Tech 40 Label DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasd
Read more →DBVTDBV Technologies to Present Viaskin Data at the 2015 EAACI Congress
Accessibility: Skip TopNav DBV Technologies to Present Viaskin® Data at the 2015 EAACI Congress April 15, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present Viaskin® Data at the 2015 EAACI Congress DBV Technologies (Euronext: DBV - ISIN: F
Read more →DBVTDBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in Children
Accessibility: Skip TopNav DBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in Children April 09, 2015 01:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Receives FDA Breakthrough Therapy
Read more →DBVTDBV Technologies Reports Full Year 2014 Financial Results
BAGNEUX, France, March 25, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced today its full year 2014 results. The audit procedures on the 2014 consolidated
Read more →DBVTDBV Technologies Appoints Daniel Soland to Board of Directors
Accessibility: Skip TopNav DBV Technologies Appoints Daniel Soland to Board of Directors March 10, 2015 02:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Appoints Daniel Soland to Board of Directors DBV Technologies (Euronext: DBV - ISIN: FR0010417345 -
Read more →DBVTDBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory Board
Accessibility: Skip TopNav DBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory Board February 13, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory Board BAGNEUX, France, February 1
Read more →DBVTDBV Technologies : Largest Presence Ever of DBV Technologies at 2015 Allergy Meeting
Accessibility: Skip TopNav DBV Technologies : Largest Presence Ever of DBV Technologies at 2015 Allergy Meeting February 03, 2015 12:30 ET DBV Technologies S.A. DBV Technologies S.A. Six Presentations Highlighting the Potential of Epicutaneous Immunotherapy (EPIT®) in the Tr
Read more →DBVTDBV Technologies to Present at the 2015 Leerink Partners Global Healthcare Conference in New-York (USA)
Accessibility: Skip TopNav DBV Technologies to Present at the 2015 Leerink Partners Global Healthcare Conference in New-York (USA) February 03, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. BAGNEUX, France, February 3, 2015 - DBV Technologies, (Euronext: DBV - IS
Read more →DBVTDBV Technologies : DBV Technologies Announces Topline Financial Results for Full Year 2014
Accessibility: Skip TopNav DBV Technologies : DBV Technologies Announces Topline Financial Results for Full Year 2014 January 29, 2015 01:30 ET DBV Technologies S.A. DBV Technologies S.A. Bagneux, France, January 29th, 2015 - DBV Technologies, (Euronext: DBV - ISIN: FR001041
Read more →DBVTDBV Technologies Announces Topline Financial Results for Full Year 2014 Bagneux, France, January 29 th , 2015 - DBV Technologies, (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage specialty b
DBV Technologies Announces Topline Financial Results January 29th, 2015 - DBV Technologies, (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced today its topline financial results, as well as its cash and
Read more →DBVTDBV Technologies : Half year update on the DBV Technologies liquidity agreement
Accessibility: Skip TopNav DBV Technologies : Half year update on the DBV Technologies liquidity agreement January 14, 2015 12:00 ET DBV Technologies S.A. DBV Technologies S.A. Half year update on the DBV Technologies liquidity agreement Bagneux, France, January 14, 2015 -
Read more →DBVTDBV Technologies Announces Publication in the Journal of Allergy and Clinical Immunology of Data Demonstrating that Epicutaneous Immunotherapy may Influence the Natural History of Allergy
Accessibility: Skip TopNav DBV Technologies Announces Publication in the Journal of Allergy and Clinical Immunology of Data Demonstrating that Epicutaneous Immunotherapy may Influence the Natural History of Allergy January 12, 2015 01:30 ET DBV Technologies S.A. DBV Technolog
Read more →DBVTDBV Technologies Provides Organizational Update
DBV Technologies Provides Organizational Update BAGNEUX, France, January 8, 2015 - DBV Technologies, (Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today provided an organizational update, which included app
Read more →DBVTDBV Technologies : Additional Contribution to the Liquidity Agreement with Natixis
Accessibility: Skip TopNav DBV Technologies : Additional Contribution to the Liquidity Agreement with Natixis December 18, 2014 08:52 ET DBV Technologies S.A. DBV Technologies S.A. BAGNEUX, France, December 18, 2014 - DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Na
Read more →DBVTAdditional Contribution to the Liquidity Agreement with Natixis
Additional Contribution to the Liquidity Agreement with Natixis BAGNEUX, France, December 18, 2014 - DBV Technologies (Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced today an additional contribution
Read more →DBVTDBV Technologies :Monthly information regarding the total number of voting rights and total number of shares of the Company Monthly information regarding the total number of voting rights and t...
Accessibility: Skip TopNav DBV Technologies :Monthly information regarding the total number of voting rights and total number of shares of the Company Monthly information regarding the total number of voting rights and t... December 08, 2014 08:27 ET DBV Technologies S.A. DBV
Read more →DBVTDBV Technologies Initiates Phase I/II Clinical Trial with Viaskin Milk for the Treatment of Children with Cow s Milk Allergy
DBV Technologies Initiates Phase I/II Clinical Trial with Viaskin Milk for the Treatment of Children with Cow s Milk Allergy BAGNEUX, France, November 20, 2014 - DBV Technologies, (Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopha
Read more →DBVTDBV Technologies (Nasdaq: DBVT) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
ADVISORY, Oct. 21, 2014 (GLOBE NEWSWIRE) -- -- DBV Technologies (Nasdaq: DBVT), a clinical-stage specialty biopharmaceutical company, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO) which will occur today, October 22. Headqua
Read more →DBVTDBV Technologies S.A. Announces Pricing of Global Offering
Accessibility: Skip TopNav DBV Technologies S.A. Announces Pricing of Global Offering October 22, 2014 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies S.A. Announces Pricing of Global Offering Bagneux, France - October 22, 2014 - DBV Technologies (Euro
Read more →DBVTDBV Technologies S.A. Announces Proposed Global Offering
Accessibility: Skip TopNav DBV Technologies S.A. Announces Proposed Global Offering October 20, 2014 13:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies S.A. Announces Proposed Global Offering Bagneux, France - October 20, 2014 - DBV Technologies (Euronext
Read more →DBVTDBV Technologies Announces Topline Financial Results for First Nine Months 2014
Accessibility: Skip TopNav DBV Technologies Announces Topline Financial Results for First Nine Months 2014 October 14, 2014 12:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Topline Financial Results for First Nine Months 2014 Bagneux, France,
Read more →DBVTDBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut's Phase IIb Clinical Trial in Peanut Allergy
Accessibility: Skip TopNav DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut's Phase IIb Clinical Trial in Peanut Allergy September 22, 2014 12:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Primary Endpoint Met in VIPES,
Read more →DBVTDBV Technologies to Attend the Goldman Sachs European Biotech Symposium
Accessibility: Skip TopNav DBV Technologies to Attend the Goldman Sachs European Biotech Symposium August 26, 2014 02:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Attend the Goldman Sachs European Biotech Symposium BAGNEUX, France, August 26, 2014 -
Read more →DBVTDBV Technologies :DBV Technologies Reports Financial Results for the First Six Months of 2014
Accessibility: Skip TopNav DBV Technologies :DBV Technologies Reports Financial Results for the First Six Months of 2014 July 28, 2014 01:30 ET DBV Technologies S.A. DBV Technologies S.A. Bagneux, France, July 28, 2014 - DBV Technologies (Euronext: DBV - ISIN: FR0010417345),
Read more →DBVTDBV Technologies Completes last "food challenge" visit of last Peanut-Allergic patient in VIPES Phase IIb Clinical Study
Accessibility: Skip TopNav DBV Technologies Completes last "food challenge" visit of last Peanut-Allergic patient in VIPES Phase IIb Clinical Study July 17, 2014 11:45 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Completes last "food challenge" visit of la
Read more →DBVTDBV Technologies to Present at Upcoming US Investors Conferences
Accessibility: Skip TopNav DBV Technologies to Present at Upcoming US Investors Conferences June 16, 2014 11:45 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present at Upcoming US Investors Conferences BAGNEUX, France, June 16, 2014 - DBV Technologies,
Read more →DBVTDBV Technologies : DBV Technologies' June 3rd, 2014 Combined shareholders' Meeting
Accessibility: Skip TopNav DBV Technologies : DBV Technologies' June 3rd, 2014 Combined shareholders' Meeting June 03, 2014 09:43 ET DBV Technologies S.A. DBV Technologies S.A. Adoption of all resolutions submitted to the vote of Shareholders BAGNEUX, France, June 3rd, 2014
Read more →DBVTDBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children
Accessibility: Skip TopNav DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children May 13, 2014 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Clinical Trial Agreement t
Read more →DBVTDBV Technologies to Host and Webcast Investor Day in New York City on May 21, 2014
Accessibility: Skip TopNav DBV Technologies to Host and Webcast Investor Day in New York City on May 21, 2014 May 12, 2014 08:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Host and Webcast Investor Day in New York City on May 21, 2014 BAGNEUX, Franc
Read more →DBVTDBV Technologies : DBV Technologies publishes its 2013 Registration Document and its 2013 Annual Financial Report
Accessibility: Skip TopNav DBV Technologies : DBV Technologies publishes its 2013 Registration Document and its 2013 Annual Financial Report April 17, 2014 06:59 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies publishes its 2013 Registration Document and its
Read more →DBVTDBV Technologies : DBV Technologies Announces Topline Financial Results for First Three Months 2014
BAGNEUX, France, April 15, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin , a new reference in the treatment of allergy, announced today its topline financial results, as well as its net cash position, for first three months 201
Read more →DBVTDBV Technologies and CEA conclude a scientific cooperation to investigate epigenetic modulation in epicutaneous immunotherapy
Accessibility: Skip TopNav DBV Technologies and CEA conclude a scientific cooperation to investigate epigenetic modulation in epicutaneous immunotherapy April 09, 2014 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies and CEA conclude a scientific coopera
Read more →DBVTDBV Technologies Announces Creation of US Subsidiary and Appoints Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & Strategy
Accessibility: Skip TopNav DBV Technologies Announces Creation of US Subsidiary and Appoints Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & Strategy April 07, 2014 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Announces Creatio
Read more →DBVTDBV Technologies Reports Full Year 2013 Financial Results and Provides VIPES Update
Accessibility: Skip TopNav DBV Technologies Reports Full Year 2013 Financial Results and Provides VIPES Update March 17, 2014 02:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports Full Year 2013 Financial Results and Provides VIPES Update Patients e
Read more →DBVTDBV Technologies to Present at the Barclays Global Healthcare Conference in Miami, USA
Accessibility: Skip TopNav DBV Technologies to Present at the Barclays Global Healthcare Conference in Miami, USA March 03, 2014 12:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies to Present at the Barclays Global Healthcare Conference in Miami, USA BAGN
Read more →DBVTDBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn's Disease
Accessibility: Skip TopNav DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn's Disease February 18, 2014 02:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn's Di
Read more →DBVTDBV Technologies Reports Full Year 2013 Topline Financial Results
Accessibility: Skip TopNav DBV Technologies Reports Full Year 2013 Topline Financial Results January 30, 2014 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports Full Year 2013 Topline Financial Results Cash Burn under control: DBV closes 2013 with
Read more →DBVTDBV Technologies Enters into Collaboration Agreement with BioNet-Asia and University of Geneva on Whooping Cough Booster Vaccine
DBV Technologies Enters into Collaboration Agreement with BioNet-Asia and University of Geneva on Whooping Cough Booster Vaccine Agreement established after positive pre-clinical results were obtained by DBV and University of Geneva combining DBV's and BioNet's unique technologi
Read more →DBVTDBV Technologies : DBV Technologies announces the completion of a €29.9m private placement with a majority placed with US investors
Accessibility: Skip TopNav DBV Technologies : DBV Technologies announces the completion of a €29.9m private placement with a majority placed with US investors November 14, 2013 03:14 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies announces the completion of
Read more →DBVTDBV Technologies : Capital increase - Launch of a private placement of new and existing shares
Accessibility: Skip TopNav DBV Technologies : Capital increase - Launch of a private placement of new and existing shares November 13, 2013 12:44 ET DBV Technologies S.A. DBV Technologies S.A. DBV to launch a private placement of new and secondary shares Bagneux, France, N
Read more →DBVTDBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin(R) for Refractory Hemophilia A Disease
BAGNEUX, France, Oct. 22, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext:DBV) (ISIN: FR0010417345), creator of Viaskin , a new standard in the treatment of allergies, announced today that it has entered into a research collaboration with Institut national de la Sant et de la
Read more →DBVTDBV Technologies initiates a long-term follow-up study of Viaskin Peanut
Accessibility: Skip TopNav DBV Technologies initiates a long-term follow-up study of Viaskin Peanut September 04, 2013 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies initiates a long-term follow-up study of Viaskin Peanut OLFUS-VIPES will be the large
Read more →DBVTDBV Technologies Reports Financial Results for the First Six Months of 2013
Accessibility: Skip TopNav DBV Technologies Reports Financial Results for the First Six Months of 2013 July 26, 2013 01:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies Reports Financial Results for the First Six Months of 2013 Bagneux, France, July 26, 2
Read more →DBVTDBV Technologies completes enrollment of Phase IIb VIPES study, the first-ever global trial in desensitization to peanut allergy
Accessibility: Skip TopNav DBV Technologies completes enrollment of Phase IIb VIPES study, the first-ever global trial in desensitization to peanut allergy July 08, 2013 02:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies completes enrollment of Phase IIb V
Read more →DBVTDBV Technologies Monthly information regarding the total number of voting rights and total number of shares of the Company
Accessibility: Skip TopNav DBV Technologies Monthly information regarding the total number of voting rights and total number of shares of the Company July 08, 2013 12:00 ET DBV Technologies S.A. DBV Technologies S.A. Monthly information regarding the total number of voting r
Read more →DBVTDBV Technologies announces breakthrough Data Presentations at EAACI-WAO Congress
Accessibility: Skip TopNav DBV Technologies announces breakthrough Data Presentations at EAACI-WAO Congress June 28, 2013 02:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies announces breakthrough Data Presentations at EAACI-WAO Congress BAGNEUX, France, J
Read more →DBVTDBV Technologies : Viaskin Peanut demonstrates strong efficacy trend in severely peanut-allergic children in 18-month results of ARACHILD pilot study
Accessibility: Skip TopNav DBV Technologies : Viaskin Peanut demonstrates strong efficacy trend in severely peanut-allergic children in 18-month results of ARACHILD pilot study June 20, 2013 01:30 ET DBV Technologies S.A. DBV Technologies S.A. Viaskin Peanut demonstrates str
Read more →DBVTDBV Technologies proudly welcomes Mrs. Veronique Foutel as Chief Strategic Marketing Officer
Accessibility: Skip TopNav DBV Technologies proudly welcomes Mrs. Veronique Foutel as Chief Strategic Marketing Officer June 06, 2013 02:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies proudly welcomes Mrs. Veronique Foutel as Chief Strategic Marketing Of
Read more →DBVTDBV Technologies' June 4th, 2013 Combined Shareholders's Meeting
Accessibility: Skip TopNav DBV Technologies' June 4th, 2013 Combined Shareholders's Meeting June 04, 2013 05:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies' June 4th, 2013 Combined Shareholders's Meeting Adoption of all resolutions submitted to the vote
Read more →DBVTDBV Technologies and Stallergenes enter into partnership for the development of innovative treatment of respiratory allergies
Stallergenes and DBV Technologies enter into partnership for the development of innovative treatment of respiratory allergies Partnership to develop immunotherapy treatments for respiratory allergies using DBV's skin patch, Viaskin® ANTONY and BAGNEUX, France, 16 May 2013 - D
Read more →DBVTDBV Technologies and Mount Sinai Hospital enter into a Research Collaboration Agreement
Accessibility: Skip TopNav DBV Technologies and Mount Sinai Hospital enter into a Research Collaboration Agreement May 07, 2013 02:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies and Mount Sinai Hospital enter into a Research Collaboration Agreement BAGNE
Read more →DBVTDBV Technologies publishes its 2012 Registration Document and its 2012 Annual Financial Report
Accessibility: Skip TopNav DBV Technologies publishes its 2012 Registration Document and its 2012 Annual Financial Report April 25, 2013 02:30 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies publishes its 2012 Registration Document and its 2012 Annual Financ
Read more →DBVTDBV Technologies' first quarter 2013 Topline and cash position
Accessibility: Skip TopNav DBV Technologies' first quarter 2013 Topline and cash position April 15, 2013 02:00 ET DBV Technologies S.A. DBV Technologies S.A. DBV Technologies' first quarter 2013 Topline and cash position Bagneux, France, April 15, 2013 - DBV Technologies (E
Read more →Competitive Position
How DBVT ranks across every disease it competes inCompetitive Position is a premium feature
See how DBVT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial